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I. Targeted β-catenin Ubiquitination and Degradation Using  
Bifunctional Stapled Peptides 
II. Studies on Cell Penetration by Stapled Peptides 
 
Abstract 
 
 Hydrocarbon-stapled α-helical peptides represent a relatively new class of synthetic 
peptidomimetics capable of inhibiting protein-protein interactions. It has been shown that 
hydrocarbon “staples” spanning one or two helical turns in a peptide increase α-helical 
content and protease resistance, enhance target binding affinity, and promote cell 
penetration. This technology has been applied to the development of cell-permeable 
ligands targeting several intracellular targets. This dissertation describes efforts to further 
the development of stapled peptide technology. 
  A bifunctional stapled peptide strategy was introduced to target a key regulator in 
the canonical Wnt signaling pathway, β-catenin, for ubiquitination and proteasomal 
degration. We designed and synthesized a panel of bifunctional stapled peptides and 
demonstrated that they can recruit the MDM2 protein, an ubiquitin E3 ligase, to β-catenin. 
An in vitro ubiquitination assay was developed to demonstrate specific β-catenin poly-
ubiquitination mediated by bifunctional peptides. Furthermore, treatment of the human 
colorectal cancer line SW480 with bifunctional stapled peptides demonstrated dose-
dependent knockdown in endogenous β-catenin levels. In addition, a reporter gene assay 
showed that the bifunctional stapled peptides can downregulate downstream gene 
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expression in the Wnt signaling pathway. Therefore, bifunctional stapled peptides may 
serve as potential pathway-specific drug candidates in the treatment of Wnt-addicted 
cancers, and are a unique research tool for probing the Wnt signaling pathway by targeted 
knockdown of β-catenin at the protein level. 
  We also studied the cell penetration property of stapled peptides, which is one of 
the most significant and poorly understood aspects of peptide stapling technology. We 
developed a high-throughput microscopy assay to quantitatively measure stapled peptide 
intracellular accumulation. Using this assay, we analyzed more than 200 discrete peptides 
with various sequences, stapling positions and types. We found that cell penetration is 
strongly related to stapling types and formal charge, i.e. stiched and cationic peptides. In 
addition, we used chemcal genetic screens to identify the specific pathway involved in 
stapled peptide internalization. These studies showed that stapled peptides penetrate cells 
through clathrin- and caveolin-independent endocytosis pathway that requires sulfated 
proteoglycans. These findings improve our understanding of stapled peptides as chemical 
probes and potential targeted therapeutics, and provide guidelines for the design of next-
generation stapled peptides. 
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Chapter I    Introduction 
 
Expanding the Druggable Genome 
 The human genome provides a great bulk of essential genetic information. It 
contains approximately 30,000 genes, most of which specify protein synthesis by 
cytoplasmic ribosomes. The proteins encoded by these genes collaborate extensively to 
form a complex interplay of signaling networks and thereby regulate a wealth of biological 
processes necessary for life1-2. Defects in critical signal transduction pathways often 
indicate the onset and progression of different types of diseases3-5. Extensive efforts have 
been made in the field of drug discovery to develop and apply therapeutic interventions to 
target disease-modifying proteins, resulting in two major classes of drugs, small molecule 
and protein therapeutics (also known as biologics)6-9.  
Small molecules are able to target, with high affinity and specificity, proteins which 
feature a deep, hydrophobic pocket on their surface10-11. Therefore, the common targets for 
small molecule therapeutics usually engage in protein-ligand interactions, such as 
receptor-ligand and enzyme-substrate/cofactor pairs12-13. The small molecule drugs 
compete against the native ligands in the already structured hollows. However, protein-
protein interactions, as a broad class of interactions highlighted in signaling networks, are 
typically characterized by an extensive association between two relatively flat yet precisely 
complementary surfaces14. As a result, developing small molecules that modulate protein-
protein interactions has proven difficult due to the lack of well-defined binding pocket at 
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protein surfaces15. Furthermore, targeting the complex signaling networks comprised of 
distinct protein-protein and protein-ligand interactions requires small molecules with 
great structural diversity, such as size, shape, functional groups and chirality16-17. Current 
synthetic strategies and designs, however, limit the accessibility of molecules with enough 
structural variation, resulting in delays in drug development. Therefore, only 
approximately 10% of proteins in the human genome can be accessed by small molecule 
therapeutics18. 
 
Figure 1.1   The druggable genome. The two major classes of drugs, small molecule and protein 
therapeutics, can each target approximately 10% of human proteins, indicating that more than 80% 
of the proteins are considered undruggable. 
Protein therapeutics, on the other hand, are now well-established as a clinically and 
commercially important class of drugs. Compared with small molecules, proteins usually 
have rich three-dimensional structures as well as diverse surface variability, making them 
suitable to accommodate different protein partners and exerting their pharmacologic 
activities. In addition, the binding affinity and specificity of protein therapeutics to their 
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targets can be optimized by a variety of selection technologies such as phage, yeast or 
ribosome display. However, the major drawback of protein therapeutics involves an 
inability to translocate across the plasma membrane, limiting their effectiveness to cell 
surface or extracellular targets. Another shortcoming of protein therapeutics is that they 
undergo fast denaturation and proteolysis in the gut and are thus usually not orally 
bioavailable. To this end, protein therapeutics are able to access an estimated 10% of 
human proteins18.  
 Each of these two classes of pharmacologic agents – small molecules and protein 
therapeutics – can access about 10% of protein targets in the human genome, indicating 
that at least 80% of human proteins are considered undruggable (Figure 1.1). Among these 
undruggable targets, there are incredibly important proteins, such as transcription factor 
“master regulators” and other key proteins that are root causes of a vast range of human 
diseases19-20. For example, c-myc transcription factor and the KRas GTPase play a pivotal 
role in many signaling cascades and are essential in numerous biological activities. 
Aberrant activation of these genes has proven to be involved in development of different 
types of cancers. However, they are considered undruggable targets since no molecule that 
directly targets either of these proteins has been reported. Therefore, access to such high 
value biological targets that are not amenable to current therapeutic intervention would 
expand treatment options and be a major boost for patients. Indeed, extensive studies have 
been performed to expand the druggable genome, and several promising results have been 
reported recently. 
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 These efforts can be characterized into several different categories. First, modern 
technological advances have been employed to revisit the human genome and proteome in 
order to search for understudied and unannotated proteins that could be potential drug 
targets21. Defining the druggable genome is an exceptional sophisticated task, as several 
parameters could influence the count, including the coverage of DNA sequence databases, 
the algorithms used for sequence annotations, and the bioinformatics tools and biological 
information about protein function. Therefore, the outcome of counting the druggable 
genome largely depends on the resources and tools used in the studies, indicating there 
might be some underestimated proteins that could be targeted by traditional therapeutic 
strategies. Considering the rapid evolvement of related technology, it is possible to expand 
the druggable genome by identifying new sets of proteins accessible by therapeutic 
molecules1-2. 
The second approach is expanding the molecular diversity by new synthetic 
strategies22-23. Most current drug discovery efforts start with high-throughput screening of 
small molecule library to search for hits that can exert noticeable phenotype changes in 
vitro or in vivo. However, traditional screening libraries are composed of large numbers of 
structurally similar compounds. It is broadly accepted now that both library size and 
structural diversity are equally important. In response to this problem, Schreiber and 
coworkers at Harvard University pioneered a new synthetic strategy, “Diversity-Oriented 
Synthesis” (DOS), which utilizes “build – couple – pair” organic synthesis to make 
compounds covering as much chemical space as possible24. The DOS strategy usually takes 
limited steps of robust chemical reactions to convert simple starting materials to a library 
of compounds with a high degree of structural diversity, measured in terms of functional 
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groups, stereochemistry, and scaffold variability (Figure 1.2)25. Several promising results 
have been reported by screening DOS library compounds against a variety of targets, 
including traditionally undruggable proteins such as BCL-2 and Sonic Hedgehog26-27. 
 
Figure 1.2   Diversity-oriented synthesis with a build-couple-pair strategy. Build: asymmetric 
synthesis of chiral building blocks. Couple: intermolecular coupling reactions with the building 
blocks synthesized in the “build” phase, which provides the basis for stereochemical diversity. Pair: 
intramolecular coupling reactions that join every possible combination of functional groups 
incorporated in the “build” phase (polar functional groups shown in blue, nonpolar in black). The 
skeletal diversity is generated in this “pair” phase. (This Figure is adapted from Reference 25) 
A third category of efforts involves discovering new therapeutics by exploiting the 
druggable genome with innovative strategies. Traditional drug discovery either starts with 
screen-based identification of target protein binders and subsequent in vivo evaluation of 
activity or begins with in vivo phenotype screenings featuring no target bias followed by 
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the target identification for the lead compounds28-30. In order to improve the efficiency of 
these approaches, several new strategies have been invented. For example, fragment-based 
drug discovery has emerged in the past decade as a new approach to discover drug leads31-
34. It starts with identifying small chemical fragments that bind only weakly to the target. 
These fragments are further expanded or linked to produce a lead with a higher affinity 
(Figure 1.3). The advantage of this strategy over conventional methods is the difference in 
the stringency of the initial screens. The starting binding affinity for a fragment-based 
screen is usually in the millimolar range, which is much easier to fulfill than micromolar-
affinity hits in conventional screens.  
 
Figure 1.3   In fragment-based drug discovery, small molecule libraries with diverse chemical space 
(shown as different colored circles) are screened for initial low affinity binding fragments, which 
undergo rounds of optimization to yield high-affinity drug-like compounds for therapeutic 
application. 
Another advantage of this strategy is the greater coverage of chemical diversity space in the 
screen, which often results in a wide collection of useful starting points for drug discovery.  
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Figure 1.4   Alanine-scanning mutational analysis was carried out on the contact surface of four 
pairs of interacting proteins, a) growth hormone and growth hormone receptor, b) VEGF and FLT1, 
c) IgG Fc region and Z domain from Staphylococcus aureus protein A, d) VEGF and VEGF-specific 
monoclonal antibody. The resulting change in the free energy of binding compared with wild-type 
protein interactions (ΔΔG) is shown by different colored amino acids, from red (the most-disruptive 
changes) to green (those with the least effect). The protein hotspots are identified as a small 
number of residues (Red) which contribute most of the free energy regarding protein-protein 
interactions. (This figure is adapted from Reference 35) 
A second example lies in the discovery of protein hotspots by assessing the binding 
energy generated by each residue present at a protein-protein interface. This demonstrates 
that although the interface itself might be largely featureless, a small subset of the residues 
involved contributes most of the free energy of binding. These so-called “hotspots” are 
usually found at the center of the contact interface, and occupy only a limited surface area 
(Figure 1.4). In this case, rather than targeting the entire flat and extended protein-protein 
interface, disrupting the contact between these critical binding residues may provide useful 
insights to discover therapeutics effective toward those undruggable targets35-37.  
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As the two major classes of drugs cannot address all current therapeutic needs, 
however, current studies to expand drug discovery and improve drug efficacy focus on 
developing new chemical probes that can access the challenging targets in human 
genome38-40. In particular, novel peptide therapeutics are becoming increasingly popular 
and have exhibited in several cases profound pharmaceutical potential. 
 
Peptide Therapeutics 
 The application of peptides in the clinic is not a new topic – certain naturally derived 
peptides have been successful drugs for many years. However, difficulties with delivery, 
stability, and synthesis are the major hurdles hampering the wide commercialization of 
peptides with therapeutic potential. With the advent of large biological and synthetic 
peptide libraries and high-throughput screening techniques, there has emerged a vast 
number of promising peptide candidates and a revived interest in the development of 
peptide therapeutics41-44. 
 The differences between peptide therapeutics and protein therapeutics are 
ambiguous and still under debate. In this thesis, “peptide therapeutic” refers to peptides or 
peptidomimetics that contain no more than 50 amino acids and can be chemically 
synthesized. It is generally accepted that peptides can bind to protein targets with high 
affinity and specificity and can ideally overcome the drawbacks in small molecule and 
protein therapeutics. As peptides are generally larger than small molecules, they feature 
enough chemical diversity to render them suitable for specifically recognizing the usually 
undruggable protein-protein interface. Yet peptides are smaller than protein therapeutics, 
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which is likely to facilitate intracellular delivery as well as the avoidance of undesirable 
immune responses45. Another advantage of peptide therapeutics lies in the accessibility of 
multiple rounds of optimization by the utilization of molecular selection technology, such 
as phage and yeast cell surface display. For example, a phage display library can contain as 
many as 1011 distinct polypeptides, providing a much larger number of candidates than 
small molecule libraries. In addition, this selection process can be iterated multiple rounds 
until a peptide with the desired affinity and specificity is discovered. Furthermore, peptides 
are synthetically achievable so that a variety of non-natural amino acids with different 
chemically modified side chains can be incorporated into peptide sequences, further 
increasing the chemical diversity of peptide therapeutics and also preventing rapid 
degradation by rendering the peptide unrecognizable to proteases. Unfortunately, peptide 
therapeutics also have several notable shortcomings that restrain the transition from lead 
compounds to commercialized drugs46-47. For example, they generally have low stability in 
plasma, are sensitive to proteases and are removed quickly from circulation, resulting in 
low bioavailability and short in vivo half-lives. In addition, most peptides are generally not 
cell permeable, and exhibit high conformational flexibility which leads to a lack of 
selectivity involving interaction with different targets within a protein family.  
Nevertheless, peptide therapeutics are making a huge impact in drug discovery and 
in the treatment of many human diseases. Table 1.1 illustrates the rapidly growing number 
of peptide drugs approved by the FDA over the past four years. It is worth noting not only 
the number of approved peptide drugs, but also their application toward a broad range of 
diseases, including those life-threatening ones which are largely incurable by conventional 
therapeutics, such as cancer, diabetes, and hepatitis C virus. Given the ongoing clinical trials 
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of many other peptide drug candidates, there will most certainly be more approvals in the 
next couple years.  
Table 1.1   Peptide drugs approved by US FDA during the period 2009 – 2012. 
 
 Current peptide drugs and those in clinical trials generally fall into three different 
categories: naturally structured peptides, macrocyclic peptides, and chemically stabilized 
peptides. In order to bind to targets with high affinity and specificity, peptide candidates 
generally need to be constrained into a folded structure. Otherwise, the structural 
flexibility will cause proteolytic lability and undesired off-target issues, especially for those 
targeting proteins with closely related homologs. Therefore, peptides with promising 
therapeutic applications are typically stabilized using one or more of a number of different 
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strategies. The first class is naturally structured peptides. Nature has already evolved a 
variety of polypeptides with constrained structures through electrostatic interactions, non-
covalent hydrophobic interactions and covalent linkage like disulfide bonds. Learning from 
these naturally occurring strategies, peptide scaffolds are chosen in which certain residues 
make contacts to help the peptide fold in a desired scaffold while the other residues can be 
mutated to optimize binding affinity and specificity. For example, cystine-knot 
miniproteins, also known as knottins, are a family of proteins that share a common fold 
containing a conserved core of three tightly interwoven disulfide bonds. This structurally 
constrained scaffold confers extraordinary thermal and proteolytic stability, whereas a 
highly diverse loop region provides enough chemical variability for specific binding to 
protein targets. Correspondingly, knottins are being explored in a variety of therapeutic 
and diagnostic applications (Figure 1.5a)48-50. Another example is avian pancreatic 
polypeptide (aPP), which contains a solvent-exposed α-helix and a type II polyproline helix 
joined by a type I β-turn. Unlike knottins, which are stabilized by conserved disulfide bonds, 
the stability of aPP results primarily from hydrophobic interactions between the interior 
residues of the two helices. The exterior surfaces, on the other hand, are utilized for target 
recognition and can be engineered for improvement of binding affinity and specificity 
(Figure 1.5b). There have thus far been many successful cases using aPP as a probe to 
modulate protein-protein interactions, which might shed a light on the potential 
therapeutic and diagnostic applications51-54.  
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Figure 1.5   Crystal structures of naturally folded peptides. a) The molecular scaffold of one protein 
in the knottin family, the E. elaterium trypsin inhibitor-II (EETI-II, PDB 2ETI) with the sequence 
illustration at bottom. The three disulfide bonds in the cystine-knot core are highlighted in yellow 
and three distinct loops are colored in orange, green and blue, respectively. b) The crystal structure 
of avian pancreatic polypeptide (PDB 1PPT) with the sequence illustration at bottom. The 
interactions between proline residues in the polyproline helix (colored in magenta) and 
hydrophobic residues in the α-helix (colored in orange) constrain the peptide in a well-folded 
structure. 
Macrocyclic peptides are another class of peptide therapeutics with defined 
structures. As bioactive natural peptides are often found to feature a ring conformation, it 
has been observed that cyclization of a linear peptide generally results in a cyclic peptide 
with considerably reduced flexibility compared to the parent peptide, which provides 
several advantages in terms of interaction with a molecular target55-57. First of all, the less 
flexible cyclized peptide is structurally pre-organized, which is entropically favorable upon 
interaction with its molecular target, resulting in a higher binding affinity. Another 
advantage of a cyclic peptide is an enhanced resistance to proteolytic degradation, 
especially by exoproteases, which leads to a longer in vivo half-life and better 
bioavailability. In this respect, many natural-product-like peptides feature macrocyclic 
motifs and have profound biological functions. For example, vancomycin and cyclosporine 
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are the most well-established cyclic peptides containing modified amino acids, and they 
have been applied in treatment of human diseases for many years (Figure 1.6)58-59. 
 
Figure 1.6   Structures of a) vancomycin and b) cyclosporine A. The pre-organized macrocylic 
backbones are entropically favorable upon binding to their molecular targets. 
Lastly, chemical stabilization is an emerging strategy to fix polypeptides in a desired 
structure, and this method has demonstrated promising results in molecular targeting and 
therapeutic applications. A variety of chemical strategies have been employed to stabilize 
peptide secondary structures. Among them, stabilized α-helical peptides are becoming 
increasingly popular chemical biology probes in modulating protein-protein interactions. 
According to previous reports, 62% of the characterized protein complexes contain an α-
helix at the protein-protein interface, highlighting the significance of the α-helical 
conformation in mediating protein-protein interactions60. Furthermore, these helical 
interfaces are generally involved in a broad range of biological functions throughout the 
entire cellular signaling network61-63. Therefore, studies have been performed to 
chemically stabilize a dominant negative peptide in its bioactive α-helical structure. The 
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stabilized α-helical peptides are expected to disrupt the targeted protein-protein interface 
and also exhibit increased resistance to proteases owing to structural rigidity as well as 
unnatural chemical moieties in some cases.  
 
Figure 1.7   Strategies of stabilization of an α-helical peptide, a) salt bridges, b) hydrophobic 
interactions, c) disulfide bonds, d) lactam-based crosslinking, e) olefin metathesis via O-allyl serine 
or homoserine, f) α-methyl, α-alkenyl all-hydrocarbon crosslinking, g) perfluoroaryl-cysteine 
crosslinking, h) hydrogen bond surrogates. 
There are three general categories of α-helical stabilization strategies as shown in 
Figure 1.7. The first category involves the introduction of non-covalent interactions, such as 
ion-pair salt bridge64 and hydrophobic interactions65, to reinforce the α-helical character. 
The second category involves covalent crosslinking of side chains, which can be achieved 
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by several different chemistry methods, including disulfide bond formation, lactam bridge 
formation, olefin metathesis of two alkenyl containing side chains and the recently 
invented perfluoroaryl-cysteine SNAr reaction66-71. The common idea behind these different 
crosslinking strategies is to employ two reactive residues on the same face of the peptide 
helix, usually spanning one or two successive α-helical turns (i.e. i, i + 4 or i, i +7 positions), 
and promote α-helix nucleation by forming the side chain bridge. A third category of 
stabilization technique is the hydrogen bond surrogate (HBS) strategy which was 
developed by Arora and coworkers72-75. A classical α-helix is stabilized by the hydrogen 
bond between the oxygen atom of carbonyl group of a residue at the i position and the 
main chain amide –NH- at the i + 4 position. Inspired by this feature, one of the main chain 
hydrogen bonds is replaced by a covalent linkage to produce a highly stabilized, internally 
cross-linked α-helix. The advantage of this strategy is that the helix surface is not disturbed 
by the constraining element, allowing them to retain binding affinity to protein targets. All 
of these methods have shown the ability to chemically stabilize an α-helical peptide, and 
ongoing efforts are focusing on the optimization of their biological activities and 
applications in therapeutic and diagnostic uses.  
 
 
All-Hydrocarbon Stapled α-Helical Peptides 
 As discussed above, an α-helical conformation can be chemically stabilized by many 
strategies. However, challenges are still present in terms of the production of stabilized α-
helical peptides with properties that are essential to drug candidates, such as robust cell 
16 
 
penetration, proteolytic resistance, and the desired biological activity. Among these 
stabilized peptides, all-hydrocarbon stapled α-helical peptides (“stapled peptides”) 
produced by  ruthenium-mediated olefin metathesis of α-methyl, α-alkenyl di-substituted 
amino acids, are of particular interest owing to their exciting promise in therapeutic 
potential since several stapled peptides are currently in clinical trials76-78.  
 Stapled peptide technology was developed by Verdine and coworkers at Harvard 
University in 2000. It employs a dominant negative strategy, in which a short α-helical 
peptide essential for target binding is chosen based on protein complex structures as a 
starting template. This small piece of peptide itself is not functional in general since it loses 
the bioactive conformation without the rest of protein as scaffolding. In order to restore the 
peptide to its bioactive α-helical conformation, two α-methyl, α-alkenyl disubstituted non-
natural amino acids are incorporated into the peptide sequence followed by formation of 
an all-hydrocarbon “staple” through olefin metathesis (Figure 1.8a)69. The peptide stapling 
strategy uniquely combines two helix-stabilizing elements: α, α-disubstitution that exerts a 
local helical bias and a covalent macrocyclic bridge that further constrains the peptide into 
an α-helical conformation. Another advantage of the all-hydrocarbon crosslink over other 
stabilization methods is that it increases the hydrophobicity of the molecule, resulting in 
improved cell penetration. Overall, the reinforcement of α-helical character assures the 
peptide retains the desired secondary structure, which would also make it bind more 
tightly, resist proteolytic degradation, and exhibit cell permeability.  
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Figure 1.8   All-hydrocarbon stapled peptide technology. a) Schematic illustration of typical peptide 
stapling. Two alkenyl-bearing non-natural amino acids are incorporated at two positions in the 
peptide chain and then cross-linked by ruthenium-catalyzed ring-closing olefin metathesis. b) 
Different types of alkenyl-containing non-natural amino acids with distinct stereochemistry at the 
α-carbon and varied lengths of alkenyl side chains. c) Four types of stapled peptides with optimized 
combinations of non-natural amino acids (Figure 1.8a is adapted from Reference 87).  
A panel of alkenyl-containing non-natural amino acids with varied stereochemistry 
at α-carbon and different lengths of alkenyl side chain have been investigated (Figure 1.8b). 
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The amino acids are named XY, where X refers to the stereochemistry (S or R) at the α-
carbon and Y is the number of carbon atoms in the alkenyl side chain. In particular, an 
achiral amino acid B5 with two 5-atom-long alkenyl side chains at α-carbon is also 
prepared, which is used for tandem stapling. By incorporating these non-natural amino 
acids into peptide sequences, several types of stapled peptides have been optimized to 
feature the best α-helical character (Figure 1.8c)79-82. Generally, the optimization of the α-
helical conformation depends on the nature of the non-natural amino acids (stereochemical 
configuration and length of alkenyl side chain) as well as their relative disposition in a 
peptide sequence. For example, two distinct stapling patterns (i, i + 3, and i, i + 4) can be 
used to obtain an all-hydrocarbon crosslink spanning approximately one α-helical turn. 
However, the optimized amino acid combination for i, i + 3 is R5 at i position and S5 at i + 3 
position, whereas in the i, i + 4 case, placement of an S5 cross-linking amino acid at both the 
i and i + 4 positions results in the most stabilized peptides. To place an all-hydrocarbon 
tether over  two successive α-helical turns, an R8 is placed at the i position and an S5 is 
placed at the i + 7 position. Recently, a new version of stapled peptide with tandem 
crosslinks, a so-called stitched peptide, was also successfully synthesized based on the idea 
that multiple staples in a single peptide will result in better α-helical stabilization. The 
stereochemistry of the non-natural amino acids are delicately aligned in stitched peptides, 
with S5 at the i position, B5 at the i + 4 position, and S8 at the i + 11 position. This 
arrangement perfectly satisfies the stereochemical requirements for two successive staples, 
and yields an 8-carbon staple over the i, i + 4 helical turn and an 11-carbon staple over the i 
+ 4, i + 11 helical turns. It is important to point out that these optimized combinations of 
non-natural amino acids are not dependent on peptide sequences – the different stapling 
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patterns can be easily grafted to many peptide sequences and result in similar α-helical 
stabilization. 
 Stapled peptide targeting is based on a dominant negative strategy, in which the 
stapled peptides are derived from a binding partner of protein targets. The original design 
principle for a typical stapled peptide is to keep all the native peptide-protein contacts 
intact by positioning the all-hydrocarbon crosslink opposite the binding interface78. The 
design process usually starts with a high-resolution protein complex structure that 
perfectly illustrates the protein-protein interface of interest. Then one binding partner is 
stripped away until a short α-helical peptide essential for binding is identified. The 
residues in the peptide sequence that make contacts with the protein target are kept 
unchanged, whereas the corresponding amino acids on the opposite face are replaced by 
alkenyl-containing non-natural amino acids. Given that the hydrocarbon staple generally 
spans one or two α-helical turns, a panel of stapled peptides is designed with all possible 
staple positions sampled. The resulting stapled peptides with the best α-helical 
stabilization are then further investigated for biological activities. Interestingly, recent 
crystallography efforts on stapled-peptide and protein target complex structures indicate 
that the all-hydrocarbon staple can also contribute to binding, revealing an extra benefit of 
the stapled peptide strategy. Figure 1.9 shows the crystal structure of the MDM2 protein 
complexed with the stapled peptide SAH-p53-8 derived from the p53 protein83. In addition 
to retaining the native association of the three essential hydrophobic residues (F19, W23 
and L26), the 11-carbon-atom staple of SAH-p53-8 also interacts extensively with MDM2. 
This observation further suggests new design principles for stapled peptide targeting at 
protein-protein interfaces. In place of the original strategy of avoiding interruption of 
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native interactions, peptides can be purposely designed with a staple right at the binding 
interface as the major driving force of the association. The biological outcome of this 
particular type of approach is under investigation. 
Figure 1.9  The crystal structure of 
stapled peptide SAH-p53-8 bound to 
MDM2 (PDB 3V3B) showing that the i, i + 
7 staple successfully constrains the p53 
derived peptide in α-helical conformation. 
The peptide retains all native interactions 
with MDM2 (shown in magenta) and the 
three key contacting residues in the 
peptide, F19, W23 and L26, are colored in 
green. Interestingly, the all-hydrocarbon 
brace itself (colored in red) also 
contributes to the binding, with its 
interacting residues colored in blue.  
 
 The stapling strategy can efficiently constrain a peptide in an α-helical conformation, 
but it does not guarantee any biological activity. The development of a stapled peptide 
possessing therapeutic potential is typically a multistep process involving iterative 
optimization of many critical properties, such as binding affinity, cell permeability, aqueous 
solubility, and in vivo activity. For example, in order to improve cell penetration, stapled 
peptides are designed with positive net charge84-85. One method is to avoid unnecessary 
negatively charged residues by the replacement of non-binding acidic amino acids, namely 
aspartic acid and glutamic acid, with asparagine and glutamine, respectively. Furthermore, 
an increase in net charge can also be accomplished by appending additional basic residues, 
especially arginine at the peptide terminus. Optimization of the binding affinity usually 
starts with screening different combinations of stapling patterns, hydrocarbon crosslink 
length, and stapling positions, while still keeping the peptide sequence similar to the 
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original one. If these attempts are unsuccessful, the stapled peptide can be further 
optimized by highly developed selection and screening techniques, such as phage and yeast 
cell surface display85-86. It is worth noting that these selection methods do not necessarily 
require a high-affinity binder as a starting point, making it possible to discover a stapled 
peptide de novo.  
 The promising features of stapled peptides suggest that they can act as a new class 
of inhibitors targeting intracellular protein-protein interfaces that have previously been 
intractable to inhibition by traditional small molecules or protein therapeutics. Indeed, 
many stapled peptides have been reported recently to show extraordinary biological 
activity against a large set of protein targets, including transcription factor complexes, 
oncoproteins, apoptotic mediators, and metabolic enzymes85, 87-90. Ongoing efforts include 
further optimization of binding affinity and specificity, improvement of bioavailability, and 
understanding the nature of staple peptides, especially their cell penetration properties.   
 
Studies on Cell Penetrating Peptides 
 The discovery of potent therapeutic peptides portends a promising future in the 
treatment of various human diseases. However, one of the major hurdles for peptides 
reaching the clinic involves poor delivery and low bioavailability, which is highlighted by 
the development of cell permeable peptide therapeutics. Peptides are generally considered 
to be non-cell permeable macromolecules because of the hydrophilic nature of the amide 
main chain. However, the past two decades have witnessed a dramatic increase in our 
knowledge of cell penetrating peptides (CPPs), a class of small peptides which are able to 
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translocate across plasma membranes. This line of study was initiated with the discovery in 
1988 that the HIV-coded Tat regulatory protein could penetrate into living cells91. Three 
years later, a second cell penetrating protein, the antennapedia homeodomain of 
Drosophila, was discovered to be taken up by cells in a non-receptor mediated manner92. A 
short peptide sequence, namely the third helix of the antennapedia protein, was 
subsequently identified sufficient for cellular internalization93. Since then, extensive 
studies have been performed regarding 1) the discovery of other polypeptides with cell 
penetration activity, 2) the investigation of the internalization mechanisms of these cell 
penetrating peptides, and 3) the application of cell penetrating peptides as drug delivery 
agents. 
 So far, hundreds of short peptides possessing cellular uptake ability have been 
characterized. Generally, these cell-penetrating peptides can be categorized into three 
different groups as shown in table 1.294-95. The first group of cell penetrating peptides is 
derived from the sequences of protein transduction domains (PTDs), which are defined as 
polypeptides that can efficiently cross biological membranes by themselves and can be 
used to facilitate the delivery of diverse cargo to the interior of mammalian cells. Discovery 
of these peptides usually starts with the identification of already existing proteins 
exhibiting cellular uptake properties and subsequently location of the minimal peptide 
sequence that promotes membrane translocation. In order words, the cell penetrating 
peptides in this category largely retain their native sequences. Among them, the Tat 
peptide (48 - 60) derived from the transactivating protein Tat of human immunodeficiency 
virus-type 1 (HIV-1), the penetratin (or Antp) peptide from the third helix of the Drosophila 
antennapedia homeodomain, and transportan, a fusion peptide with 12 residues from 
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neuropeptide galanin coupled to the N-terminus of another peptide mastoparan are the 
most well-studied cell penetrating peptides. These CPPs have been used to deliver a variety 
of non-permeable macromolecules such as peptides, proteins, and oligonucleotides into 
cells.  
Table 1.2    Examples of typical cell penetrating peptides. 
 
A second category of cell penetrating peptides is amphipathic peptides, which are 
largely discovered by de novo design and feature little biological homology. Regardless of 
the specific cell penetration pathway, the first step in uptake should be a strong association 
with the cell membrane. The major characteristic of a plasma membrane is an amphipathic 
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phospholipid bilayer with an interior hydrophobic core and a negative net charge owing to 
the phospholipid headgroups and the embedded proteoglycan molecules. In order to gain a 
strong interaction with the plasma membrane, peptides are often designed as amphipathic 
molecules having both polar and non-polar residues in their sequences to best 
accommodate the hydrophobic yet negatively-charged character. In particular, the 
amphipathicity of these peptides can result from peptide primary sequences by sequential 
assembly of a domain of hydrophobic residues with a domain of hydrophilic residues (i.e. 
Pep-1 and MPG), as well as their secondary structures in which hydrophobic and 
hydrophilic residues are positioned on opposite sides of the peptide (i.e. MAP and KALA). 
Indeed, plenty of amphipathic peptides designed using both strategies show robust cell 
penetration properties. In addition, there also exist several other cell penetrating peptides 
which have been developed using other criteria. For example, cationic polypeptides such as 
polyarginine, polylysine, and dendrimeric polycationic peptides emphasize on the role of 
positive charges in the internalization process.  
In order to design next generation cell penetrating peptides with improved cellular 
uptake properties, it is crucial to understand the mechanisms of penetration. There are 
several different methods reported for the evaluation of the cell penetration of peptides. 
The most common method is to label a peptide of interest with a fluorophore and to 
measure the fluorescence of treated cells. For example, confocal microscopy imaging is 
used to monitor the presence as well as the subcellular localization of internalized peptides. 
Fluorescence-activated cell sorting (FACS) is another frequently used method to 
quantitatively measure the uptake of labeled peptides56, 89. The major issue with this 
method is that the fluorescence analysis cannot discriminate internalized peptides from 
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those bound at the cell surface, and a majority of cell penetrating peptides are known to 
interact with the cell membrane and are difficult to completely remove by washing. To this 
end, fluorophore-free strategies have been applied to study the cellular uptake of peptides. 
For example, Schepartz and coworkers have coupled peptides with a small molecule, 
dexamethasone (Dex), that can trigger the dimerization and nuclear accumulation of the 
glucocorticoid receptor (GR). Treatment of cells expressing a GR-GFP fusion protein with 
Dex-peptide conjugates leads to rapid cytosol-to-nucleus translocation of the GFP signal if 
the peptide is able to access the cytoplasm. Therefore, the cell penetration ability can be 
assessed by determining the ratio of GFP signal in the nucleus versus the cytosol96. This 
method successfully circumvents fluorophore-related problems, but it prevents the study 
of the dynamics of the internalization process, especially the initial association of the 
peptides with the cell membrane. On the other hand, different biophysical methods and 
model systems have been utilized to understand the mechanisms of CPP translocation97. 
For example, the cellular uptake process can be systematically monitored by transmission 
electron microscopy (TEM), or a large unilamellar phospholipid vesicle (LUV) can be used 
as model membranes to study lipid-peptide interactions. 
These distinct strategies greatly enrich our ability to study cell penetration, but the 
mechanisms by which CPPs enter cells are still under debate. The controversial results are 
in part due to the different strategies used in the studies, but are also due to the 
complicated nature of CPPs98. For example, the translocation mechanisms are believed to 
be different for peptides from different families, and it is entirely possible that one peptide 
can utilize two or more pathways to enter cells99. Generally, there are two major uptake 
mechanisms: direct penetration and energy-dependent endocytosis, each of which is 
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supported by a list of observations97. Direct penetration is an energy-independent process 
that may include different pathways, such as inverted micelle formation and pore 
formation100-101. For example, pore-formation penetration starts with interaction between 
the peptide and the cell membrane, followed by peptide barrel formation in the lipid 
bilayer in which hydrophobic residues are close to the lipid chains and hydrophilic 
residues form the central pore. On the other hand, energy-dependent endocytosis is also 
believed to be employed by several CPPs since their penetration ability decreases 
dramatically at 4℃ or in ATP-depleted cells102-104. Endocytosis is an energy-consuming 
process through which cells absorb molecules by engulfing them. It consists of several 
pathways including phagocytosis for uptake of particles larger than 0.75 µm in diameter, 
macropinocytosis, and receptor-mediated endocytosis, such as clathrin- and caveolin-
dependent endocytosis105-106. The uptake mechanism of CPPs have been extensively 
investigated using strategies that typically employ small molecule inhibitors to block 
certain cell uptake pathways which CPPs are believed likely to utilize. However, 
controversial and often contradictory conclusions are commonly received. For the Tat (48 -
60) peptide, early studies suggested a direct penetration model in which the peptide 
associates with the plasma membrane through electrostatic interactions, disrupting the 
membrane enough to allow the peptide to cross the membrane. However, this mechanism 
has been questioned recently, and a macropinocytosis pathway, in particular clathrin-
mediated endocytosis, has been proposed104, 107-108. Additionally, it is likely that there are 
important unidentified factors regulating the intracellular trafficking process. Taken 
together, hundreds of cell penetrating peptides with little sequence homology exhibit 
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robust cellular uptake, and there is believed to be no single answer to the mystery of how 
CPPs traverse the cell membrane.  
All-hydrocarbon stapled peptides as a new class of potentially therapeutic 
molecules have been observed to penetrate the cell membrane at micromolar 
concentrations through one or more energy-dependent uptake mechanisms that remain 
unidentified. The work presented in this thesis has focused on systematic elucidation of the 
cell penetration processes and the development of stapled peptides that hijack an 
endogenous ubiquitin-proteasome pathway to exhibit improved biological activity. 
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Chapter II    Targeted β-catenin Ubiquitination and Degradation Using 
Bifunctional Stapled Peptides 
 
The Canonical Wnt Signaling Pathway  
The Wnt (Wingless and Int-1) signaling cascade regulates a large number of 
biological activities from early development to adult life in all animals. The discovery of 
Wnt signaling was initiated in 1982 by identification of the Wnt1 gene (originally named 
Int-1), a proto-oncogene encoding a secreted, cysteine-rich protein which is activated upon 
integration of mouse mammary tumor virus in virally induced breast tumors1. The 
homolog of Wnt-1 gene in Drosophila melanogaster was discovered five years later in 19872. 
It was determined to be the previously characterized Drosophila gene known as Wingless, 
which controls segment polarity during larval development3. Since then, a variety of genes 
have been identified as core components in the Wnt signaling cascade, and significant 
progress has been made toward understanding the mechanism of the Wnt regulation in 
health and disease4-5. 
The term “Wnt signaling” does not simply stand for a single purpose signal 
transduction pathway. Rather, it refers to a diverse collection of pathways triggered by Wnt 
ligand-receptor interactions that regulate cell behavior in multiple ways, such as cell 
polarity, proliferation, differentiation, survival and self-renewal6. Diversity in Wnt signaling 
is derived from the large number of its components, including 19 Wnt ligands, 10 receptors, 
as well as its signaling transduction components7. The most well-known Wnt pathway is 
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the highly conserved canonical Wnt/β-catenin signaling pathway, which regulates the 
stability of the transcription coactivator β-catenin and subsequent β-catenin-dependent 
gene expression8.  
 
Figure 2.1   The canonical Wnt signaling pathway with its major components in the “Wnt OFF” (Left) 
and “Wnt ON” (Right) states. BCL9 and CBP are transcriptional coactivators. 
The canonical Wnt signaling pathway initiates following the engagement of secreted 
Wnt proteins with the receptors at cell membrane, which causes an accumulation of β-
catenin in the cytoplasm and its eventual translocation into the nucleus to activate 
transcription factors belonging to the T cell factor/lymphoid enhancer factor (TCF/LEF) 
family and thereby enhances downstream gene expression9. In this manner, β-catenin 
serves as a hub to connect the canonical Wnt signal from the plasma membrane to the 
nucleus. In the absence of Wnt ligands, the cytosolic β-catenin protein level is kept low due 
to phosphorylation-dependent ubiquitination and degradation. A multicomponent 
destruction complex for β-catenin is assembled by the association of scaffolding protein 
Axin, tumor suppressor protein adenomatous polyposis coli (APC), casein kinase 1 (CK1) 
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and glycogen synthase kinase 3 (GSK3). Phosphorylation of β-catenin is performed by the 
sequential action of CK1 and GSK3 on residues Ser45 and Ser33, Ser37, Thr41, respectively. 
Phosphorylated β-catenin is then recognized by β-Trcp, an E3 ubiquitin ligase subunit, and 
is ubiquitinated and degraded through the ubiquitin-proteasome pathway (Figure 2.1 
Left)10-11.  
Upon Wnt stimulation, the Wnt proteins associate with a heterodimeric receptor 
complex consisting of two distinct membrane bound proteins. One belongs to the Frizzled 
(Fz) family of serpentine proteins, and the other is low-density-lipoprotein receptor related 
protein LRP5/6. The binding of Wnt ligands to the LRP receptor induces phosphorylation 
on the cytoplasmic tail of LRP protein, which provides a docking site for Axin association. 
Meanwhile the intracellular domain of Wnt ligand bound the Fz receptor interacts with 
Dishevelled (Dsh) protein, facilitating the interaction between the LRP tail and Axin. The 
engagement of Axin to the plasma membrane via LRP disrupts the β-catenin destruction 
complex, resulting in the inhibition of β-catenin phosphorylation and its subsequent 
degradation. Consequently, the accumulated β-catenin undergoes translocation to the 
nucleus, where it recruits powerful transcription coactivators, such as CREB-binding 
protein (CBP) and B-cell lymphoma 9 protein (BCL9) to DNA-bound transcription factors of 
the TCF/LEF family and eventually activates downstream gene expression (Figure 2.1 
Right)12-13.  
Activated Wnt signaling serves a critical role in many tissue types during embryonic 
development14. In adults, activated Wnt signaling also has an essential function in stem cell 
maintenance and tissue regeneration15. Given the importance of Wnt signaling in stem cell 
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biology, it is not surprising that inappropriate activation of Wnt signaling is strongly 
implicated in the initiation and progression of several types of cancer16. For example, 
approximately 90% of colorectal cancers are associated with high-level of constitutive 
activation of Wnt signaling17. In most cases, aberrant activation of the Wnt signaling 
pathway results from the reduced ability of the destruction complex to recruit and degrade 
β-catenin. Mutations and truncations have been found in APC, Axin and β-catenin itself to 
prevent formation of the destruction complex5. Recent studies reveal that malfunctioning 
of the Wnt signaling pathway is not only involved in the onset of numerous cancers, but 
also results in many other diseases, for example, metabolic disease, bone disease, and etc.18-
19 Therefore, targeting the Wnt signaling pathway is of particular interest in treatment of 
human diseases. 
 
β-catenin - an Appealing Target in Drug Discovery 
 The broad involvement of Wnt signaling in disease has driven extensive research 
efforts at targeting the Wnt pathway with small molecules. Several compounds, as listed in 
Table 2.1, have been reported to inhibit Wnt-dependent signaling by phenotypic screening 
of small molecule libraries20-25. Among them, the most promising compounds so far either 
inhibit tankyrase, an Axin destabilizer (XAV939 and IWR-1), or activate CK1α (pyrvinium), 
which affect Wnt signaling primarily by stimulating the activity of the β-catenin destruction 
complex. Although these efforts have provided valuable tool compounds, the therapeutic 
utilities are limited by the fact that most disease-causing mutations are either in APC or in 
pathway components downstream of the destruction complex26. Additionally, tankyrase 
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and CK1α are involved in many other cellular processes, increasing the risk of undesirable 
off-target effects. The most effective target in the canonical Wnt signaling pathway is β-
catenin, since it serves as a critical junction in signaling and operates downstream gene 
expressions. However, direct targeting of β-catenin protein has yielded limited success thus 
far. 
Table 2.1   Small molecule inhibitors in the canonical Wnt signaling pathway. 
 
The β-catenin protein is a conserved dual function protein exerting a crucial role in 
developmental and homeostatic processes. Besides its function in signal transduction in 
canonical Wnt signaling cascade as discussed above, β-catenin plays a second role in 
regulating the coordination of cell-cell adhesion by association with the cytoplasmic tail of 
cadherin family proteins27. Human β-catenin is a protein with 781 residues, consisting of a 
central region (residues 141-664) made up of 12 Armadillo (ARM) repeats, which is 
flanked by distinct N- and C-terminal domains, NTD and CTD respectively.  A conserved 
helix-C (residues 667-683) is located proximally to the CTD, adjacent to the last ARM 
repeat28. The NTD and the CTD are structurally flexible, but the central armadillo domain is 
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a relatively rigid scaffold, which serves as an interaction platform for many binding 
partners, and thereby involved in diverse cellular processes (Figure 2.2). 
.  
Figure 2.2   Schematic illustration of β-catenin and its interacting partners in adherens junctions, 
cytoplasm and nucleus. β-catenin is shown as 12 Armadillo repeats flanked by N- and C-terminal 
domains. The interacting proteins are colored in different categories according to their biological 
activities. The disposition of each interacting partner represents the binding region on β-catenin 
protein.  
From the perspective of blocking Wnt signaling in cancer, the most obvious 
approach would be to target the β-catenin and TCF/LEF interface directly. However, as 
shown in Figure 2.3, TCF associates with β-catenin protein with an extended binding 
interface of approximately 60 Å in length29. The lack of a deep hydrophobic pocket in β-
catenin, the typical region of intervention for a small molecule inhibitor, has resulted in 
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limited success with inhibitors from this class. Although several compounds, such as 
PKF115-854, have been suggested to disrupt β-catenin and TCF/LEF interaction, their 
specificity and efficacy are yet to be characterized (Table 2.1)24. Therefore, direct targeting 
β-catenin at the TCF/LEF binding surface is an appealing challenge in the inhibition of the 
canonical Wnt signaling pathway. 
 
Figure 2.3   Superimposed crystal structure of the β-catenin armadillo domain bound to the β-
catenin-binding-domain (CBD) of Axin (PDB 1QZ7) and TCF4 (PDB 2GL7). The CBD of Axin and 
TCF4 helical region overlap the binding surface with opposite orientations. 
 
Stapled Peptides as Direct Inhibitors Targeting β-catenin Protein  
The Verdine Lab at Harvard University has developed and applied the all 
hydrocarbon stapled α-helical peptide technology to target several intracellular proteins, 
including apoptotic mediators30, and multi-protein transcription factor complexes31. Given 
the difficulty in the identification of small molecule antagonists to target β-catenin and 
TCF/LEF interface, we saw the potential utility of stapled peptides in this system. This 
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strategy was further rationalized by the presence of the requisite α-helical peptide at the 
binding surface (Figure 2.3)32. As a result, we took advantage of the fact that the β-catenin-
binding-domain (CBD) of Axin protein overlaps the binding surface with TCF helical region, 
characterized stapled Axin-derived (StAx) peptides that function as direct β-catenin 
antagonists in vitro and in cultured cells through a systematic approach including screening 
of candidate stapling positions, affinity optimization via phage display, and introduction of 
residues that promote cell penetration. The crystal structure of β-catenin/StAx complex 
revealed that the stapled Axin peptide binds at the same site as Axin-CBD and the TCF 
helical region. Moreover, these peptides, but not closely related negative control molecules, 
interfered specifically with transcriptional activation of canonical Wnt pathway genes. In 
addition, the most active stapled peptide induced growth inhibition of Wnt-dependent 
cancer cells, but did not affect the growth of cancer cells that do not rely on deregulated 
Wnt signaling pathway33.  
 
Bifunctional Stapled Peptides as Improved β-catenin Antagonists 
 In order to further improve the biological activity of stapled Axin peptide inhibitors 
(StAx), a bifunctional stapled peptide strategy that additionally harnesses the regulation of 
protein homeostasis by ubiquitin-proteasome system was employed to improve 
antagonistic efficiency in targeting β-catenin (Figure 2.4).  
Ubiquitin is a small, highly conserved protein that is attached to lysine residues on 
proteins targeted for degradation through the sequential actions of ubiquitin-activating 
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enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligase (E3). Successive 
conjugation of ubiquitin to previously attached ubiquitin molecules on the substrate 
protein results in a polyubiquitin chain that is recognized by the 26S proteasome, 
ultimately leading to degradation of the target protein34. 
 
Figure 2.4    Schematic diagram of β-catenin ubiquitination and degradation by bifunctional stapled 
peptides. The β-catenin binding part in the bifunctional peptide is colored in purple, whereas the 
MDM2 binding part is colored in orange. The process starts with MDM2 recruitment to β-catenin, 
followed by poly-ubiquitination of β-catenin protein, which is eventually recognized and degraded 
by 26S proteasome.  
In this approach, StAx peptides were proposed to conjugate with a second stapled 
peptide which can recruit an endogenous ubiquitin ligase to β-catenin protein. In doing so, 
the new bifunctional stapled peptides would not only inhibit β-catenin activity by 
interfering with β-catenin/TCF interactions, but would also trigger its ubiquitination and 
subsequent fast degradation by the proteasome system inside cells. In addition, given that 
stapled peptides are usually resistant to intracellular proteolysis, the bifunctional stapled 
peptides may be considered catalytic β-catenin antagonists, since they can facilitate the 
ubiquitination and proteasomal degradation process in multiple turnovers.  
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The concept of bifunctional molecules that specifically bring two or more proteins 
together for improved or novel biological effect has been established for decades. A 
bifunctional small molecule can be as simple as a natural product that interacts with two 
proteins simultaneously. For example, FK506 and rapamycin are macrocyclic 
immunosuppressive molecules bound to the same immunophilin, FKBP, with similar 
structural elements, which compose half of the macrocycle. The distinct chemical moieties 
from the other half of the macrocycle endow them a unique binding surface for a second 
protein partner: calcineurin for the FK506-FKBP complex, and mTOR for the rapamycin-
FKBP complex. It is through this second interaction that these molecules derive different 
biological activities35-36. Subsequently, variants of these molecules have been engineered to 
bind to orthogonal proteins known as “chemical inducers of dimerization”37. Since then, the 
field has expanded with new molecules and new applications in chemical genetics and cell 
biology38. In particular, the Deshaies and Crews lab developed a novel class of bifunctional 
molecules named as the PROTACS (proteolysis targeting chimeric) molecules, designed to 
exploit the ubiquitin-proteasome system and selectively degrade targeted proteins39. 
Typically, a PROTAC molecule is made up of two ends, one of which can be recognized by 
an E3 ubiquitin ligase, while the other binds to a protein target. Therefore, the targeted 
protein is recruited to the E3 ligase for ubiquitination and followed by proteasomal 
degradation. So far, this approach has been successfully applied to several protein targets 
by distinct E3 ligases40-41. Unlike the common gene knockout or RNAi technology, this 
method provides a useful research tool for study of protein function through controlled 
knockdown of target proteins at the post-translational stage, thereby avoiding many issues 
related with classic genetic approaches. Despite the potential of PROTAC technology as an 
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investigative toolkit, the poor cell penetration limits its widespread application. In this 
study, bifunctional stapled peptides are also generated with the intention of hijacking 
ubiquitin-proteasome system, but have the potential to exhibit better cellular and in vivo 
activity, as stapled peptides have been demonstrated to efficiently cross the cell membrane.  
 
The Design and Synthesis of Bifunctional Stapled Peptides 
As discussed above, the goal of this project is to synthesize bifunctional stapled Axin 
(Bisax) peptides by conjugation of β-catenin binding StAx peptides with another stapled 
peptide which can recruit an E3 ubiquitin ligase to β-catenin and thereby induce the 
ubiquitination and degradation via endogenous ubiquitin-proteasome system. StAx-35 was 
used in this study as a β-catenin binder because it exhibits the best binding affinity to β-
catenin in a panel of stapled axin peptides with a dissociation constant of low nanomolar 
range.  
Table 2.2 Stapled Axin (StAx) and SAH-p53-8 peptides and their respective negative controls. 
 
For an E3 ubiquitin ligase binder, a stapled peptide SAH-p53-8 which derived from the 
tumor suppressor p53 protein, was demonstrated to bind to MDM2, an E3 ubiquitin ligase 
with high affinity and specificity according to our previous results42. Therefore, SAH-p53-8 
was chosen to conjugate with StAx-35 peptide to recruit the E3 ligase MDM2 to β-catenin 
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target.  In addition, negative control stapled peptides for StAx-35 and SAH-p53-8 were also 
included here as building blocks for negative control bisax peptides which could not bind to 
either protein (Table 2.2). 
 
Figure 2.5 Bifunctional stapled Axin (Bisax) peptides. (a) Schematic illustration of the linkage of 
bisax. (b) Bisaxes used in this study with varied orientation and linker length, where “f” means 
FITC-labeled, “S” and “L” mean short and long linker, respectively, and “X” means negative control 
peptides.  
Unlike bifunctional small molecules that can rotate freely around the central linker 
to accommodate themselves in the binding pockets of protein targets, the binding of 
bifunctional peptides to their targets is more constrained by the peptide orientation. 
Improper orientation around the linker, as well as suboptimal linker lengths may cause 
unexpected steric clashes between the two binding proteins. Due to the lack of crystal 
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structure information for full length β-catenin or MDM2, it is difficult to completely 
rationalize the optimal peptide orientations and linker length based on their partial 
structures. Therefore, bisax peptides were made with all four possible orientations and 
with a linker length varied from approximately 25 Å (2 × PEG1) to 100 Å (4 × PEG2). In 
doing so, we aimed to screen for the best combinations as determined by biological activity 
in vitro and in cell-based assays (Figure 2.5). 
For the conjugation, a thiol-malaimide Michael addition was used to link the two 
stapled peptides together because it is a fast and high yield reaction and most importantly 
in this study, it creates a non-cleavable covalent bond between the two peptides, which 
keeps the bisax peptide intact in in vitro assays and inside cells43. Specifically, a cysteine 
residue was coupled at either N- or C-terminus of the StAx peptides, whereas a maleimide 
moiety was appended on SAH-p53-8 peptides. These were synthesized and HPLC purified 
separately. The final product was obtained by in-solution Michael addition of the two 
peptide precursors and followed by a second round of HPLC purification. As a result, a total 
of 10 bisax peptides with varied orientations and linker length were synthesized with >95% 
purity as verified by LC/MS (Figure 2.5).  
 
Analysis of Binding of Bifunctional Stapled Peptides 
In order to confirm that the bifunctional stapled Axin (Bisax) peptides retain the 
binding affinity to both β-catenin and MDM2 proteins, an in vitro fluorescence polarization 
(FP) assay was performed. FP assay measures the polarization of light emitted by 
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fluorophore labeled molecules at unbound and bound states. Typically, the fluorophore 
labeled compound is usually small and rotates rapidly, which generates low polarization. 
Upon binding to a larger molecule, its rotation slows down dramatically, and a high 
polarization signal can be observed. Thus, dissociation constant (Kd) can be calculated 
when fitting the polarization values into a sigmoidal curve44. In this study, a fluorescein 
isothiocyanate (FITC) labeled bisax-20F was prepared by coupling a FITC label at SAH-p53-
8 end of bisax-5 peptide. N-terminal FITC labeled StAx-35 and SAH-p53-8 were synthesized 
as previously reported33, 42. Human β-catenin and MDM2 full length proteins were 
expressed in E. coli and purified using a modified version of reported protocols28, 45. 
(Details in Experimental Methods) 
The fluorescence polarization assays were carried out in triplicates. The raw data 
were imported into GraphPad Prism (GraphPad software), and were subjected to 
normalization where 0% bound stands for non-bound state, and 100% bound indicates a 
fully bound state. The normalized data were then plotted and fitted to Hill equation with 
simultaneous weighting of the standard deviations of each data point.  
Hill equation:                  
  
 
     
The Hill equation for binding is listed above, where m1 is the polarization at the 
unbound state, m2 is the polarization at the saturated bound state, m3 is the dissociation 
constant (Kd), and m4 is the Hill coefficient, which usually indicates the cooperativity of the 
binding interaction.  
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Figure 2.6 shows the fluorescence polarization results. As expected, StAx-35 binds 
to β-catenin protein with a Kd of approximate 40 nM, which is consistent with previous 
reports, whereas SAH-p53-8 stapled peptide shows no quantifiable binding to β-catenin. 
Bisax-20F is a fluorescein labeled peptide where StAx-35 and SAH-p53-8 are conjugated 
through N-terminus-N-terminus linkage. It exhibits a binding affinity of approximate 60 nM 
when incubated with β-catenin protein, an affinity close to that of StAx-35 stapled peptide. 
(Figure 2.6a) Similar results were observed when these FITC labeled peptides were 
incubated with the MDM2 protein. SAH-p53-8 and bisax-20F bind to the MDM2 protein 
tightly, with Kd values of 34 and 38 nM respectively. However, StAx-35 could not bind to 
MDM2 protein at all (Figure 2.6b). Taken together, FP binding assay results show that bisax 
peptides can bind to β-catenin and MDM2 protein separately, and the binding affinity of 
bsax-20 is comparable to StAx-35 and SAH-p53-8 alone. 
 
Figure 2.6   Fluorescence polarization assays showing that bifunctional stapled peptide retains 
binding affinity to β-catenin and MDM2 proteins. a) Bisax-20F binds to β-catenin protein with 
similar affinity as StAx-35. b) Bisax-20F binds to the MDM2 protein with similar affinity as SAH-
p53-8.  
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The fluorescence polarization assay above raised several questions regarding to the 
binding abilities of bisax peptides. For example, only bisax-20F with N-terminus-N-
terminus linkage and two polyethylene glycol spacers was tested, the binding properties 
for the rest of bisax peptides with different orientations and varied linker length are still 
unknown. In addition, although bisax-20F has similar binding affinity to β-catenin and 
MDM2 protein as StAx-35 and SAH-p53-8 respectively, it is unclear from these results 
whether it binds at the same sites of the target proteins. 
In order to address these questions, a competition fluorescence polarization assay 
was carried out. FITC-labeled StAx-35 (or SAH-p53-8) was pre-incubated with β-catenin 
(or MDM2) protein to generate a bound state which produces a high fluorescence 
polarization signal. The concentration of β-catenin (or MDM2) protein was chosen based 
on the FP assay where 80% of the protein was bound to the FITC-labeled peptide. Then 
non-labeled bisax peptides were then added at increasing concentrations, aiming to 
compete with the bound FITC-StAx-35 (or FITC-SAH-p53-8). If they bind at the same sites, 
FITC-StAx-35 (or FITC-SAH-p53-8) will be displaced, resulting in a low polarization 
unbound state. However, if non-labeled bisax peptides could not bind to the target proteins 
or they bind at a different site, the polarization signal will stay high. Polarization values 
were plotted and fitted into sigmoidal curve to yield an IC50 which can be used to compare 
the binding affinity for different bisax peptides.  
As shown in Figure 2.7, the active compound bisax-8 can bind to β-catenin (and 
MDM2) protein tightly and competes with FITC-StAx-35 and FITC-SAH-p53-8 which causes 
decrease in polarization signal with IC50 values of 0.285 ± 0.014 µM and 0.242 ± 0.016 µM 
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respectively. However, the negative control peptide bisax-25 cannot compete either of the 
FITC-labeled peptides at all. This in vitro competition FP assay confirms the bind ability of 
bisax peptides to both β-catenin and MDM2 protein, and indicates that they bind at the 
same site on target proteins as StAx-35 and SAH-p53-8. 
 
Figure 2.7   Competition fluorescence polarization assay with increasing amount of bifunctional 
stapled peptides against a) β-catenin and b) MDM2 protein. The active bisax-8 peptide competes 
with both StAx-35 and SAH-p53-8 peptides, whereas the negative bisax-25 cannot, which indicates 
that bifunctional peptides bind at the same site on target proteins as each of the un-ligated peptides.  
In order to compare the binding affinity for all bisax peptides and thereby analyzing 
the effect of peptide orientations and linker length, the competition FP assay was applied to 
all the bisax peptides against β-catenin. In particular, bisax-5, 8, 11 and 14 are compounds 
with all four possible orientations and the same 2 × PEG2 linker (~ 50 Å). With this linker, 
the peptide orientation did not have any significant effect with regard to their binding 
properties. All of the four bifunctional peptides exhibited similar binding affinities to β-
catenin, ranging from 0.285 to 0.593 µM (Figure 2.8a). Similarly, the linker length does not 
appear to affect the measured binding properties either. As shown in Figure 2.8b, bisax-8, 
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23 and 24 are peptides with N-terminus of StAx-35 linking to C-terminus of SAH-p53-8, 
whereas the linker length varies from approximately 25 Å to 100 Å. However, they can 
efficiently compete with FITC-StAx-35 with similar IC50 values.  
 
Figure 2.8   Competition fluorescence polarization assays using bisax peptides with a) different 
orientations and b) varied linker length showing that both peptide orientation and linker length do 
not appear to affect the measured binding properties. 
Based on competition FP assay results, a better understanding of the binding 
properties for bisax peptides can be achieved. 1) All bisax peptides, except the negative 
control bisax-25, retain their binding ability to target proteins individually. 2) Binding is 
minimally influenced by peptide orientation and linker length. 3) Bisax peptides bind at the 
same site of β-catenin (or MDM2) protein as StAx-35 (or SAH-p53-8) stapled peptides. 
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Evaluation of MDM2 Recruitment to β-catenin 
 According to the in vitro FP and competition FP assay results, bisax peptides can 
bind to β-catenin and MDM2 protein separately with high affinity. Next, we wanted to 
determine whether bisax peptides were able to recruit MDM2 to β-catenin. A pull-down 
assay was employed to address this question. The in vitro pull-down assay is a useful 
biochemistry technique to determine physical interactions between two or more 
components. Typically, a “bait” protein is tagged and captured on an immobilized affinity 
ligand specific for the tag, which is then incubated with a protein source containing 
putative “prey” proteins, such as a cell lysate. After rigorous wash, the bound proteins are 
eluted, separated by SDS-PAGE gel and confirmed by western blotting46. In this study, the 
prediction is that bisax peptide will recruit the MDM2 protein to β-catenin, generating a β-
catenin-bisax-MDM2 interacting complex. To assay for such a complex, the β-catenin was 
expressed as N-terminal GST fusion protein and immobilized on glutathione coated agarose 
resin as a “bait” protein. The “prey” MDM2 protein was from HEK293T cell lysate instead of 
purified MDM2 protein to mimic a cellular environment. Given the MDM2 protein 
expression level in mammalian cells is usually low, a stable HEK293T cell line which can 
constitutively overexpress N-terminal myc-tagged human MDM2 full length protein was 
generated by transiently transfection of a mammalian expressing neomycin-resistant 
plasmid encoding MDM2 protein followed by G418 selection. Cell lysate from this stable 
HEK293T cell line were incubated with bisax peptides at increasing concentrations in 
order to analyze the complex formation in dose-dependent manner. The bound MDM2 
protein was eventually eluted after three rounds of washing and visualized by western 
blotting following standard protocol (Details in Experimental Methods).  
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Figure 2.9    In vitro pull-down assay shows bisax-8 recruits MDM2 protein to beads immobilized β-
catenin in dose-dependent manner. 
The pull-down assay result using bisax-8 is shown in Figure 2.9. Lane 1 shows that 
myc-tagged MDM2 full length protein expressed well in HEK293T cells. When no β-catenin 
or bisax-8 was added in the mixture, MDM2 protein cannot be visualized on the gel (Lane 2 
and 3), indicating that there is no non-specific binding between MDM2 protein and 
glutathione beads or β-catenin protein, and therefore all the MDM2 signals observed in 
following lanes result from specific bisax recruitment. Interestingly, when increasing 
amount of bisax-8 were added into the mixture, bound MDM2 was first increased (Lane 4 - 
7) to reach a plateau and then decreased afterwards with a threshold approximately 500 
nM. To rationalize the result, the immobilized β-catenin is not saturated with bisax-8 up to 
500 nM, so all bisax-8 peptide is supposed to bind to β-catenin protein and thereby 
increasing the amount of bound MDM2 protein from cell lysate. However, the immobilized 
β-catenin is saturated by bisax-8 at concentration of approximately 500 nM. If bisax-8 
concentration continues to increase, the leftover non-bound bisax-8 will compete with β-
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catenin bound peptide in MDM2 binding, causing a decrease in MDM2 association. When 
bisax-8 concentration is high enough to saturate both immobilized β-catenin and MDM2 
protein from cell lysate, no signal can be observed, which is shown in Lane 10, where the 
majority of MDM2 protein is competed off at highest concentration of 10 µM. In addition, it 
is noteworthy that the result was based on the equal amount of immobilized β-catenin in 
all experiments according to immunoblotting of β-catenin loading control. 
The pull-down assay above shows that bisax-8 can efficiently recruit MDM2 protein 
to β-catenin target in the context of HEK293T cell lysate. The same experiment was carried 
out for all bisax peptides in order to investigate the effects of varied peptide orientations 
and linker length. In this experiment, the concentration of bisax peptides was chosen as 
500 nM based on the maximum MDM2 signal in bisax-8 pull-down assay.  
 
Figure 2.10   Bifunctional stapled peptides with varied orientations and linker length exhibit 
different pull-down activity, where “S” and “L” stand for short and long linker, respectively, and “X” 
means negative control peptides. 
As shown in Figure 2.10, these bisax peptides indeed exhibit different pull-down 
activities. Lanes 4 – 7 are peptides with the same 2 × PEG2 linker but different orientations. 
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It turns out that all of four possible linkage can recruit MDM2 to β-catenin protein, but 
bisax-5 with N-N linkage is the most efficient, followed by bisax-8 and 11 with either N-C or 
C-N linkage which have similar activity in MDM2 pull-down, whereas bisax-14 with C-C 
orientation is the worst. It is possible that the C-C linkage with this 2 × PEG2 linker causes 
steric clashes between β-catenin and MDM2 protein, and the N-N linkage is the best to 
accommodate the two proteins. As for the different linker length, the longer linker always 
shows better pull-down activity (Lane 8, 9 and 10, 11), which could be attributed to the 
larger number of degrees of freedom to fit both proteins together. Importantly, the 
negative bisax-25 peptide shows no activity in MDM2 pull-down since it cannot bind to 
either β-catenin or MDM2 protein (Lane 12). 
 
Figure 2.11   SAH-p53-8 and StAx-35 can compete with bisax peptides in MDM2 pull-down assay, 
indicating the recruitment of MDM2 to β-catenin is a reversible process and both SAH-p53-8 and 
StAx-35 contribute to the binding. 
In order to confirm the pull-down assays results, as well as to verify that MDM2 
recruitment is reversible in the cell lysate context, a competition pull-down assay was 
performed, in which increased concentrations of StAx-35 or SAH-p53-8 stapled peptide 
was added into the incubation mixture to compete with bisax peptides. As a result, both 
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SAH-p53-8 (Figure 2.11 Left) and StAx-35 (Figure 2.11 Right) can efficiently compete with 
bisax-8 in MDM2 protein pull-down in dose-dependent manner. Taken together, the in vitro 
pull-down assays indicate that 1) bisax peptides can efficiently recruit the MDM2 ligase to 
β-catenin protein, and this process is concentration-dependent, 2) the peptide orientation 
and linker length indeed play a significant role in forming this β-catenin-bisax-MDM2 
complex, and in current study, the N-N linkage with the longest 4 × PEG2 spacer is the best 
combination, 3) the recruitment of MDM2 to β-catenin is reversible, which can be 
disrupted by incubation with either StAx-35 or SAH-p53-8 stapled peptide. 
 
Assessment of in vitro Activity of Bisax Peptides 
The biochemistry assays above show that bisax peptides can bind to β-catenin and 
MDM2 protein simultaneously and thereby recruit the MDM2 protein to β-catenin target. 
We next wanted to verify that MDM2 can ubiquitinate β-catenin when the two proteins are 
in close proximity. Given that this is a new system and β-catenin and MDM2 proteins are 
not native ubiquitination partners, several questions needed to be addressed when 
analyzing the activity of bisax peptides. 1) Is an E3 ligase still functional on a non-native 
substrate if they are brought into close enough proximity? The majority of previous studies 
have tested ubiquitination reactions of an E3 ligase with its native substrates, and little is 
known about the activity of an E3 ligase on a non-related substrate47-48. As far as we know, 
the β-catenin protein does not have any specific interaction with MDM2, and β-catenin is 
not in the known substrate list of MDM2 ligase. However, in this study, bisax peptides can 
bind to both β-catenin and MDM2 protein simultaneously to form a β-catenin-bisax-MDM2 
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complex, which creates an association between the two proteins. In this case, MDM2 has 
the potential to be active on β-catenin protein even though they are not native 
ubiquitination partners. 2) Does β-catenin have any lysine residues that can be ubiquitin-
modified near the interacting MDM2 ligase? In the ubiquitination process, a ubiquitin 
molecule is covalently conjugated to a certain lysine side chain through an isopeptide bond. 
In this case, the target protein at least needs to have a lysine residue near the E3 ligase 
binding site as a ubiquitin receptor. The β-catenin protein has 26 lysine residues in total, 
which are spread over different domains according to crystal structure data28. Thus, it is 
entirely possible that at least some of the lysine residues will be near the MDM2 binding 
site, although it is difficult to predict the exact binding region in β-catenin due to the lack of 
a full-length MDM2 protein structure. To address this problem, a panel of bisax peptides 
was synthesized with varied orientations and linker length in order to figure out the 
peptide with optimal composition. 3) What is the ubiquitination pattern if MDM2 can 
ubiquitinate β-catenin target? Ubiquitination reactions have two different patterns: poly-
ubiquitination and mono-ubiquitination49. Both of them occur natively in cells, and each of 
them has distinct biological activities. However, the mechanism by which it is decided that 
a substrate is mono- or poly-ubiquitinated is still not clear. In order for β-catenin to be 
degraded by 26S proteasome, it needs to be poly-ubiquitinated with a ubiquitin chain 
consisting of at least four ubiquitin molecules. 
With these concerns in mind, an in vitro ubiquitination assay was developed based 
on previous protocols50. In detail, human UBA1 full length protein and UbcH5c were chosen 
as ubiquitin E1 and E2 enzymes respectively, and were expressed and purified from E. coli 
as N-terminal His6-tagged proteins. The E3 ligase human MDM2 protein and MDM2 
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inactive C464A mutant were purified using the same protocol as previously used for FP 
assays. The β-catenin protein with a C-terminus AviTag, a BirA biotin ligase recognition 
sequence, was coexpressed with BirA biotin ligase, in situ biotinylated in E. coli, and 
purified following the same protocol as the β-catenin protein used in the FP assays. The 
biotinylated β-catenin was immobilized on streptavidin agarose resin during the 
ubiquitination reaction with addition of all required enzymes, which then underwent 
stringent washing to remove all the other components. The advantage of this method is 
that the ubiquitinated protein can be visualized using both β-catenin and ubiquitin 
antibodies, whereas in previous protocol the bands observed using ubiquitin antibody 
might also come from the reaction of other components, particularly the autoubiqutination 
of E3 ligase. 
 
Figure 2.12   In vitro ubiquitination assay shows bisax-8 can induce β-catenin poly-ubiquitination 
by recruiting E3 ubiquitin ligase MDM2. a) The ubiquitination reaction only occurs in presence of 
active bisax-8 peptide, and the reaction with Me-Ub confirms the formation of poly-ubiquitination 
chain on β-catenin. b) Inactive MDM2 mutant C464A cannot produce poly-ubiquitinated β-catenin, 
highlighting the significance of MDM2 in the process. 
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Shown in Figure 2.12 are the in vitro β-catenin ubiquitination assay results. 
Promisingly bisax-8 could successfully induce the ubiquitination of β-catenin as visualized 
from β-catenin blotting, whereas the negative control bisax-25 could not (Figure 2.12a, 
Lane 2 and 3). In addition, no ubiquitination occurred when no bifunctional peptide was 
added into the reaction, confirming that the ubiquitination reaction was mediated by bisax 
peptide, not the non-specific interactions between the two proteins (Figure 2.12a Lane 1). 
However, a ubiquitination ladder shown in lane 3 does not necessarily indicate poly-
ubiquitination because mono-ubiquitination at multiple sites on β-catenin protein would 
also generate the same pattern on gel. In order to address this question, the wide-type 
ubiquitin protein was replaced by methylated ubiquitin in the ubiquitination reaction. The 
methylated ubiquitin has all seven lysine residue capped by methyl group and therefore is 
unavailable to form polyubiquitin chains51, which is widely used in ubiquitination assays to 
determine different ubiquitination patterns. In this study, only a single ubiquitinated β-
catenin band can be observed in the presence of methylated ubiquitin, indicating a poly-
ubiquitination reaction of β-catenin protein (Figure 2.12a Lane 4). In addition, to confirm 
the importance of MDM2 ligase in β-catenin ploy-ubiquitination, MDM2 C464A mutant 
protein was used as E3 source in in vitro ubiquitination assay. This MDM2 mutant has a 
cysteine to alanine mutation at the catalytic RING domain, which is unable to chelate to the 
Zn2+ ion and hence loses the ubiquitin ligase activity47. As expected, no reaction was 
observed, which indicates that the poly-ubiquitination of β-catenin target is dependent on 
recruited MDM2 ligase as well (Figure 2.12b).  
According to our in vitro ubiquitination assay, the β-catenin ubiquitination reaction 
depends on the presence of both bisax peptides and MDM2 protein. A specificity assay was 
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performed to confirm that MDM2 protein can only ubiquitinate β-catenin target with this 
panel of bifunctional peptides. The same experiment was repeated using KRas or c-myc 
protein as substrate instead of β-catenin. KRas, c-myc and β-catenin proteins are different 
in size and tertiary structures, and none of them are the native ubiquitination substrate of 
MDM2 ligase52-53. However, they have comparable number of lysine residues, which is 
adequate for potential ubiquitin modification. Neither KRas nor c-myc protein exhibited 
ubiquitination activity even though the amount of MDM2 protein was three times that used 
in β-catenin ubiquitination assay (Figure 2.13). Therefore, we can conclude from this in 
vitro ubiquitination assay that MDM2 could specifically poly-ubiquitinate β-catenin 
substrate only in the presence of bisax peptides. 
 
Figure 2.13 In vitro ubiquitination assays using a) KRas and b) c-myc protein as substrates 
indicate that bifunctional peptides promote the ubiquitination of β-catenin specifically. 
Next I examined the different activities in mediating β-catenin ubiquitination for the 
entire panel of bisax peptides. As shown in Figure 2.14, there was no ubiquitination 
reaction without bisax peptides or with negative control bisax-25. All the other bisax 
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peptides exhibited similar activities except for bisax-14, which has the least competency to 
produce ubiquitinated β-catenin. Recall from the in vitro pull-down assay that bisax-14 is 
the peptide that pulls down the least amount of MDM2 protein from HEK293T lysate. This 
suggests that the ubiquitination activity is correlated with the ability to recruit MDM2 to β-
catenin protein. 
 
Figure 2.14   In vitro β-catenin ubiquitination assay using bisax peptides with varied orientations 
and linker length, where “S” and “L” stand for short and long linker, respectively, and “X” means 
negative control peptides. 
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Analysis of Cell Penetration of bisax peptides 
 The in vitro assays show bisax peptides can not only recruit MDM2 protein to β-
catenin target with high affinity, but also trigger specific poly-ubiquitination of β-catenin 
protein. The logical next step would be to study the activity of these bifunctional peptides 
in cell-based assays to determine whether they could induce β-catenin degradation and 
regulate downstream gene expression. Before performing any cell-based experiments to 
address these questions, we verified the cell penetration properties of bisax peptides. In 
previous studies, both StAx-35 and SAH-p53-8 peptide are good cell penetrators and are 
biological active in mammalian cells33, 42. But the bisax peptides in this study are doubled in 
size and molecular weight, thus, it is necessary to assure their cell permeable abilities and 
compare with StAx-35 and SAH-p53-8 stapled peptides. 
As shown in Figure 2.15, a concentration-dependent cell penetration assay was 
performed for StAx-35, SAH-p53-8 and Bisax-20F by treatment of HeLa cells for 4 hours at 
37℃. StAx-35 and SAH-p53-8 showed good cell permeability starting at 5 µM, which is 
consistent with published results. Interestingly, bisax-20F starts to penetrate cells at 1 µM, 
and the penetration ability at 5 and 10 µM are similar as the two stapled peptides. This 
result indicates that the double-sized bisax peptides can efficiently translocate the cell 
membrane and exhibit even better permeation at lower concentrations than the stapled 
peptide counterparts.  
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Figure 2.15   Cell penetration study of bifunctional stapled peptides. (a) Image view and (b) 
quantitative measurement of cell penetration show that bifunctional peptides can efficiently cross 
cell membrane and exhibit better penetration that each un-ligated stapled peptide at 1 µM.  
 
Endogenous β-catenin Knockdown in SW480 Cells 
 With the confirmation of cell penetration for the bisax peptides, a cell-based assay 
was carried out to determine the cellular activity of these bifunctional peptides. Human 
colorectal cancer line SW480 was used in this study, which have a high level of endogenous 
β-catenin expression levels due to APC truncation, resulting in the failure to form the β-
catenin destruction complex54. Total β-catenin protein was visualized by western blotting 
after treatment of SW480 cells with bisax peptides, and the results are shown in Figure 
2.16. Bisax-11 exhibits a dose-dependent knockdown of β-catenin protein in SW480 cells 
with an IC50 approximately 50 µM, whereas the negative control bisax-25 shows no 
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reduction in β-catenin level at a concentration as high as 100 µM. The result is very 
promising, indicating the efficacy and specificity of bisax peptides in cancer cell lines. 
However, one can argue that the activity observed from this assay might result from StAx-
35 alone, because StAx-35 can bind to β-catenin specifically with high affinity and exhibits 
modest intracellular activity according to previous experience.  
 
Figure 2.16   Bifunctional peptides can specifically knockdown endogenous β-catenin protein 
levels in SW480 cells as visualized by western blotting the β-catenin amounts upon treatment of (a) 
bisax-11, (b) bisax-25, (c) StAx-35 and (d) SAH-p53-8. 
In order to confirm that both StAx-35 and SAH-p53-8 fragments in bisax peptides 
are indispensable in acquiring their cellular activities, the same experiment was performed 
with treatment of only StAx-35 or SAH-p53-8. SAH-p53-8 does not appear to have any 
activity in knockdown of endogenous β-catenin level even at a concentration of 100 µM. 
StAx-35 does not show any activity below 100 µM, and a modest activity can be observed 
as the concentration reaches 100 µM. Taken together, these results indicate that bisax 
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peptides exhibit improved cellular activity in knockdown of intracellular β-catenin proteins, 
and this activity depends on both StAx-35 and SAH-p53-8 fragments. 
 
Luciferase Activity Suppression 
As discussed above, β-catenin protein acts as a transcriptional coactivator in the 
canonical WNT signaling pathway. The accumulated cytosolic β-catenin migrates into 
nucleus, binds to TCF/LEF transcription factors, recruits other transcriptional coactivators 
and initiates downstream gene expression. In order to further characterize the biological 
activity of bisax peptides inside mammalian cells, a luciferase reporter gene assay was 
performed as a simplified model to analyze β-catenin-dependent gene expressions. SW480 
cells were transiently transfected with a plasmid encoding the firefly luciferase gene driven 
by a promoter containing four tandem TCF binding sites. Therefore, its expression was 
dependent on cellular β-catenin levels and is variable in different experiment conditions. 
Meanwhile, SW480 cells were also cotransfected with a renilla luciferase gene driven by a 
constitutive CMV promoter for signal normalization. Upon treatment of bisax peptides for 
24 hours, luciferase levels were determined by measuring the emitted luminescence after 
incubation with their individual substrates. The ratio of firefly/renilla luciferase level 
indicated the relative gene expression profile due to bisax peptide treatment and could be 
compared among different experiments. 
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Figure 2.17    Luciferase reporter gene assay showing suppression of luciferase upon treatment of 
bisax-11 peptide in a dose-dependent manner. However, the negative bisax-25 does not have any 
suppression activity. 
 As shown in Figure 2.17, treatment of bisax-11 exhibits a dose-dependent decrease 
in downstream firefly luciferase with an IC50 of approximately 60 µM, which is similar as 
the inhibition activity in knockdown of endogenous β-catenin protein in SW480 cells. 
Negative control peptide bisax-25 did not suppress the luciferase expression at a 
concentration as high as 100 µM. Given that StAx-35 can bind to β-catenin target with high 
affinity and specificity by competing the binding with TCF/LEF transcription factor, we 
wanted to rule out the possibility that the luciferase suppression observed in this assay is 
resulted from StAx-35 alone. To address this question, the same experiment was carried 
out by incubation of SW480 cells with only SAH-p53-8 or StAx-35 peptide. As shown in 
Figure 2.18, SAH-p53-8 exhibits no effect on luciferase levels, whereas StAx-35 shows 
modest luciferase suppression only at the highest concentration of 100 µM. At first glance, 
this result is not consistent with our previous experiments where StAx-35 could efficiently 
inhibit β-catenin mediated transcriptional activity in luciferase reporter assay. However, in 
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our previous study, HeLa cells were stimulated with Wnt3a conditioned medium to 
increase intracellular β-catenin levels, resulting in a highly robust expression of 
downstream genes. The observed luciferase suppression activity of StAx-35 was based on 
attenuation of the artificially elevated β-catenin which is much more abundant than that in 
Wnt-dependent cancer cells. The experiment in this study was more stringent, which 
assesses the knockdown of endogenous β-catenin in SW480 cells without any manipulation. 
Therefore, the data shown here indicated that bisax peptides have a better biological 
activity than StAx-35 in the environment of a beta-catenin driven cancer line, and the 
activity is gained from induced ubiquitination and proteasomal degradation by recruitment 
of MDM2 ligase.  
 
Figure 2.18   Luciferase reporter gene assays with SAH-p53-8 and StAx-35 indicate that the 
suppression of luciferase by bifunctional peptides requires both un-ligated stapled peptides. 
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Conclusion 
In this study, a bifunctional stapled peptides strategy was employed to target the β-
catenin protein for ubiquitination and proteasomal degration, which is a key regulator in 
the canonical WNT signaling pathway. I designed and synthesized a panel of bifunctional 
stapled Axin (bisax) peptides and demonstrated through biochemical assays that they can 
recruit the MDM2 protein, a ubiquitin E3 ligase, to the β-catenin target. I also developed an 
in vitro ubiquitination assay to show a specific β-catenin poly-ubiquitination mediated by 
bisax peptides. Furthermore, treatment of bisax peptides in human colorectal cancer line 
SW480 showed knockdown in endogenous β-catenin levels in a concentration-dependent 
manner. In addition, a dose-dependent decrease in luciferase expression was observed in 
luciferase reporter gene assay as well, indicating that bisax peptides can downregulate 
downstream gene expression in the WNT signaling pathway. These data suggest that bisax 
peptides may serve as a potential drug candidate in treatment of WNT-addicted cancers in 
a pathway specific manner, and can also be a useful research tool for better understanding 
the WNT signaling pathway by targeted knockdown of β-catenin at protein level. 
 
Future Directions 
The work in this study shows promising results in the development and application 
of bifunctional stapled peptides as potential drug candidates as well as unique research 
tools in WNT-dependent diseases. In order to further optimize the system and apply this 
technology to other challenges, future studies should be focused on the following aspects. 
72 
 
1) Introduction of cooperative binding to β-catenin and MDM2 proteins. The work in 
this study is based on the strategy that bisax peptides can recruit MDM2 protein to β-
catenin target by binding to both proteins simultaneously. We varied the peptide 
orientations and linker length, and demonstrated their binding abilities to both proteins. 
Following studies can be performed to optimize the peptide sequences as well as linker 
length to introduce a cooperative binding to β-catenin and MDM2 proteins, which would 
facilitate the recruitment of the MDM2 protein to β-catenin targets.  
2) Identification of ubiquitination sites on β-catenin protein. This study shows that 
bisax peptides can efficiently poly-ubiquitinate β-catenin protein by recruitment of MDM2 
ligase. Future studies should identify the ubiquitination sites on β-catenin target. This can 
be accomplished by mass spectrometry studies together with an in vitro ubiquitination 
assay with β-catenin mutants. Once the ubiquitination sites are identified, efforts may be 
directed towards distinguishing the differences between induced ubiquitination in this 
study and its native ubiquitination by the native β-Trcp ubiquitin ligase. Furthermore, we 
also need to figure out the effect of bisax peptides with varied orientations and linker 
length. For example, do they trigger the ubiquitination reaction on the same sites? If not, 
what sites are preferred in proteasomal degradation? Can we further optimize the activity 
of bifunctional peptides by adjusting its ubiquitination sites? Studies on these questions 
will definitely improve our understanding of bifunctional stapled peptide strategy.  
3) Assessment of downstream gene expression in the WNT signalling pathway. In this 
study, bisax peptides could knockdown endogenous β-catenin levels in human colorectal 
cancer line SW480 cells and suppress luciferase gene expression in luciferase reporter 
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assay. However, the downstream gene expression profiles in the WNT signalling pathway 
were untested. An RT-PCR or microarray experiment needs to be carried out to determine 
the effect of bisax peptides on β-catenin-dependent gene expressions. In addition, a 
pathway specificity assay is also needed to confirm that bisax peptides only show activity 
on the WNT signalling pathway. 
4) Test the activity of bifunctional stapled peptides in animal models. If bisax peptides 
exhibit good activity in above assays, an in vivo assay needs to be performed to determine 
their efficacy in animal models.  
5) Optimization of bifunctional stapled peptides. In order to further improve the 
biological activity of bisax peptides, optimizations need to be performed, which can be 
based on the following strategies: a) increase the reactivity in polyubiquitination by 
adjusting peptide orientations and linker length, b) enhance the cell penetration ability by 
peptide sequence modification, c) employ other β-catenin binding peptides or recruit other 
E3 ligases to ubiquitinate β-catenin protein with better efficiency. 
6) Application of bifunctional stapled peptides strategy to other protein targets. Our 
bifunctional stapled peptide strategy provides a useful research tool to manipulate the 
phenotype of cells by targeted knockdown of specific proteins. This study established a 
platform and performed initial tests using β-catenin as substrate and MDM2 as E3 
ubiquitin ligase. However, it can be easily expanded to other protein targets if a stapled α-
helix peptide binder can be discovered. Moreover, given the large number of ubiquitin 
ligases in human genome, it is entirely achievable to develop multiple bifunctional stapled 
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peptides to target a single protein to allow for optimization of target ubiquitination and 
proteasomal degradation.  
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Materials and Methods 
Plasmids.  
1. pET28a-UBA1. Human UBA1 gene sequence was generated by PCR amplification using 
reverse transcribed cDNA pool from HEK293T cells as template.  The primers are: 
5’BamHIE1, GGGGATCCATGTCCAGCTCGCCGCTGTCCAAGAAACG, and 3’NotIE1, GCTTAT 
GCGGCCGCTCAGCGGATGGTGTATCGGACATAGGG. PCR products were subcloned into 
pET28a vector (Novagen) using BamHI and NotI cleavage sites. The resulting construct 
contains an N-terminal hexahistidine tag. 
2. pMCSG7-TEV-UBE2D3. Human UBE2D3 gene (UbcH5c) sequence was generated by 
PCR amplification using reverse transcribed cDNA pool from HEK293T cells as template. 
The primers are: 5’KpnITEVE2, CTAGGGTACCGAGAACCTGTACTTCCAATCCATGGCGCTG 
AAACGGATTAATAAGGAAC, and 3’EcoRIE2, CTACGAATTCTCACATGGCATACTTCT 
GAGTCCATTCCC GAG. PCR products were subcloned into pMCSG7 vector (Verdine lab 
DNA database #1426) using KpnI and EcoRI cleavage sites. The resulting construct 
contains a TEV cleavage site between N-terminal hexahistidine tag and UbcH5c protein. 
3. pMAL-TEV-bCat. Human β-catenin DNA sequence was generated by PCR amplification 
using pET28b-β-catenin (Verdine Lab DNA database #2558) as template. The primers 
are: 5’BamHIbCat, GTGCGGATCCATGGCTACTCAAGCTGATTTGATGG, and 3’SalIbCat, 
GGCGGTCGACTTACAGGTCAGTATCAAACCAGGC. PCR products were subcloned into 
pMAL-TEV vector (Verdine Lab DNA database #1721) using BamHI and XhoI cleavage 
sites. The resulting construct encodes MBP fusion human β-catenin full length protein 
with a TEV cleavage site between N-terminal MBP tag and β-catenin protein. 
4. pMAL-TEV-bCat-AVI. This construct is a gift from Dr. Johannes Yeh. 
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5. pGEX-5x-bCat. This construct is a gift from Dr. Johannes Yeh. 
6. pMAL-TEV-myc-MDM2. Human MDM2 gene sequence was PCR amplified using 
pcDNA3.1(+)-HA-hDM2 (Verdine lab DNA database #1716) as template. The primers 
are: 5’BamHImycMDM2, GCGGGATCCGAACAAAAACTTATTTCTGAAGAAGATCTGGGTGG 
TATGGTGAGGAGCAGG, and 3’XhoIMDM2, GGCTCGAGCTAGGGGAAATAAGTTAGCAC 
AATC. PCR products were subcloned into pMAL-TEV vector (Verdine Lab DNA database 
#1721) using BamHI and XhoI cleavage sites. The resulting construct contains a TEV 
cleavage site between N-terminal MBP tag and myc-tagged MDM2 protein. 
7. pMAL-TEV-myc-MDM2 C464A. This MDM2 mutant was generated by site-directed 
mutagenesis (QuikChange II XL kit from Stratagene) using pMAL-TEV-myc-MDM2 as 
template. The primers are: C464A forward, CTTATGGCCTGCTTTACAGCTGCAAAGAAGC 
TAAAG, and C464A reverse, CTTTAGCTTCTTTGCAGCTGTAAAGCAGGCCATAAG.  
8. pCMV-myc3-MDM2. This mammalian cell expressing construct was purchased from 
Addgene (Plasmid 20935). It encodes human MDM2 full length protein with a 3 × myc 
tag at N-terminus. 
9. pGL-TOPflash. This mammalian cell expressing construct encodes firefly luciferase 
gene driven by a promoter containing four tandem TCF DNA binding sequences. It is 
from Verdine lab DNA database #2561. 
10.  pGLTK-renilla Luciferase. This construct is from Verdine lab DNA database #2174, 
which constitutively expresses renilla luciferase in mammalian cells. 
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Stapled Peptide Synthesis. All peptides were synthesized following an established 
protocol using standard Fmoc-peptide chemistry on Rink amide MBHA resin in NMP55. 
Briefly, Fmoc deprotection of the N-terminal amine was carried out in 25% piperidine in 
NMP for 2 × 10 minutes with nitrogen bubbling. After deprotection, the resin was washed 
with NMP 3 × 2 minutes. The coupling reaction was generally performed by adding a 
mixture of 10 equivalents of the amino acids, 9.9 equivalents of HCTU and 20 equivalents of 
DIPEA in NMP. The reactions were allowed to proceed for one hour generally or longer if 
coupling an amino acid with difficult stretch of residues. Coupling of non-natural amino 
acids (S5, R8 or PEG linker) was performed with 4 equivalents of the amino acid, 3.9 
equivalents of HCTU and 10 equivalents of DIPEA in NMP for two hours. The metathesis 
reaction of olefin containing non-natural amino acid was generally performed using 
Grubbs-I catalyst (benzylidene-bis(tricyclohexylphosphine)-dichlororuthenium) dissolved 
to approximately 10 mg/mL in dichloroethane (DCE) for two hours under nitrogen 
bubbling. After olefin metathesis, resin was wash extensively with DCE to remove excess 
Grubbs-I catalyst. Stapled peptides were then N- or C-terminal modified following standard 
coupling procedures with a variety of functional moieties, including fluorescein 
isothiocyanate (FITC), acetic anhydride, and maleimidopropionic acid. Upon completion, 
peptides were simultaneously cleaved from resin and deprotected using a cleavage cocktail 
containing 95% TFA, 2.5% water and 2.5% TIS. Peptides were cleaved at room 
temperature with gentle rotating for 3 hours. The resin was dried through nitrogen flow. 
An excess of cold diethyl ether was added to the acidic resin and peptide slurry to 
precipitate the peptide. The pellet was collected after centrifuge at 3500 rpm for 20 
minutes, and washed with cold diethyl ether one more time. The resulting crude peptide 
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precipitate was dried , dissolved in 50% acetonitrile/water, passed through a 0.2 µm 
syringe filter and were generally purified with a 10% - 70% linear acetonitrile gradient in 
water containing 0.1% TFA over 20 minutes by reverse phase HPLC using a C-18 column 
(Agilent, Palo Alto, CA). Compound identification and purity was assessed using coupled 
LC/MS (Agilent, Palo Alto, CA). Purified fractions were pooled and evaporated to remove 
acetonitrile and trace TFA by speedvac. The resulting liquid was lyophilized to dryness and 
stored as dry stock at 4℃. For biochemical and cell-based assay usage, peptides were 
dissolved in DMSO and quantified by absorbance at 280 nm if Tryptophan is present or at 
494 nm when FITC labeled. Following quantification, peptides were stored as DMSO stocks 
at -20℃ until use. 
 
Bisax Peptide Synthesis. Bifunctional stapled Axin (Bisax) peptides were generated by 
Michael addition of terminal Cysteine in SAH-p53-8 peptides and maleimide group in StAx 
peptides. The two peptides were synthesized and HPLC purified separately and stored as 
DMSO stock solution at -20℃. The reaction proceeded as 1:1 mixture of these two peptides 
in 50 % acetonitrile/PBS at room temperature for 1 hour. In some cases, a 1.5 equivalent of 
TCEP was first incubated with Cysteine containing SAH-p53-8 peptides at room 
temperature for 15 minutes followed by adding maleimide containing StAx peptides. The 
crude product was purified by reverse phase HPLC following the same protocol as each 
individual peptide (Figure 2.19). The purity of bisax pepides was tested >95% according to 
the LC/MS results (Table 2.3). The purified bisax peptides were dissolved in DMSO, 
quantified by 280 nm absorbance and stored at -20℃ until use. 
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Figure 2.19   HPLC trace of purified bisax peptides measured at 280 nm. 
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Table 2.3   List of bisax peptides with their chemical formula, molecular weight, calculated and 
found mass. 
 
 
Protein Expression and Purification.  
1. His6-UBA1. N-terminal His6-tagged human UBA1 full length protein was expressed in 
Escherichia coli strain BL21(DE3) pLysS (Stratagene) using construct pET28a-UBA1. 
Transformed bacteria was grown at 37℃ until an OD600 = 0.4 was reached, at which point 
the culture was induced with a final concentration of 0.4 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). Induced cells were grown at 16℃ for 16 hours, before 
harvest by centrifugation at 3500 rpm/4℃ for 20 minutes. Cell pellets were washed with 
PBS once, then flash frozen in liquid nitrogen and stored at -80℃ until use.  
 Lysis Buffer: 50 mM Tris pH 8.0, 200 mM NaCl, 10% (v/v) glycerol, 10 mM 
Imidazole pH 8.0, 1 mM PMSF and 1 pill protease inhibitor (Roche) with a total 
volume of 50 mL for 2L culture. 
 Washing Buffer: 50 mM Tris pH 8.0, 10% (v/v) glycerol, 10 mM Imidazole pH 8.0.  
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 Elute Buffer: 25 mM Tris pH 8.0, 100 mM NaCl, 10% (v/v) glycerol, 250 mM 
Imidazole pH 8.0. 
 Dialysis Buffer: 50 mM Tris pH 8.0, 100 mM NaCl, 10% (v/v) glycerol, 1 mM DTT. 
 MonoQ Buffer A: 50 mM Tris pH 8.0, 5% (v/v) glycerol, 1 mM DTT. 
 MonoQ Buffer B: 50 mM Tris pH 8.0, 5% (v/v) glycerol, 1 mM DTT, 1M NaCl. 
 Gel Filtration Buffer: 25 mM Tris pH 8.0, 200 mM NaCl, 10% (v/v) glycerol, 0.5 mM 
DTT. 
To purify His6-UBA1 protein, the pellet was thawed in lysis buffer at 4℃, and then 
the resuspended cells were lysed by sonication on ice (10 seconds pulses at power 6.5 for 2 
minutes). The lysate was centrifuged at 14,000 rpm for 30 minutes to precipitate insoluble 
fractions. The clarified lysate was added to approximately 2 mL of Ni-NTA agarose resin 
(Qiagen) that had been washed once with 1 × TBS. The lysate and beads slurry was 
incubated at 4℃ for 1 hour with gentle mixing in order to allow binding of His6-UBA1 
protein to the resin. The protein bound bead slurry was washed with 1L washing buffer 
with salt gradient from 300 mM to 100 mM. Retained protein was then eluted with 4 mL 
elution buffer. The eluted protein was dialysed overnight at 4℃ to remove excess imidazole. 
The protein was loaded onto a MonoQ 5/50 GL ion exchange FPLC column (GE Healthcare) 
with a linear gradient of 0-60% MonoQ buffer B over 40 column volumes. The desired 
protein was pooled and concentrated to 1 mL using a centrifugal concentrator with 30K 
MWCO (Pall Corporation). The concentrated protein was then loaded onto a Superdex 200 
gel filtration column (GE Healthcare) for buffer exchange and further purification. The 
purity of resulting pooled fractions 21 – 24 was confirmed > 95% by SDS-PAGE. The 
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purified His6-UBA1 was quantified by 280 nm absorbance, aliquot 100 µL in each PCR tube, 
and stored at -80℃ until use. 
 
Figure 2.20   His6-UBA1 purification. a) Coomassie staining of different fractions. b) MonoQ ion 
exchange column trace and coomassie stain of each fraction. c) Gel filtration column trace and 
coomassie stain of each fraction. 
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2. His6-UbcH5c. Human UbcH5c protein was expressed as an N-terminal His6-tagged 
fusion protein in Escherichia coli strain BL21(DE3) pLysS (Stratagene) using construct 
pMCSG7-TEV-UBE2D3. Transformed bacteria was grown at 37℃ until an OD600 = 0.8 was 
reached, at which point the culture was added with isopropyl β-D-1-thiogalactopyranoside 
(IPTG) to a final concentration of 0.4 mM. Induced cells were grown at 18℃ for 16 hours, 
before harvest by centrifugation at 3500 rpm/4℃ for 20 minutes. Cell pellets were washed 
with PBS once, then flash frozen in liquid nitrogen and stored at -80℃ until use. 
 Lysis Buffer: 20 mM Tris pH 8.0, 300 mM NaCl, 2% (v/v) glycerol, 10 mM Imidazole 
pH 8.0, 1 mM PMSF and 1 pill protease inhibitor with a total volume of 50 mL for 2L 
culture. 
 Washing Buffer: 25 mM Tris pH 8.0, 2% (v/v) glycerol, 10 mM Imidazole pH 8.0.  
 Elute Buffer: 25 mM Tris pH 8.0, 100 mM NaCl, 10% (v/v) glycerol, 250 mM 
Imidazole pH 8.0. 
 Gel Filtration Buffer: 50 mM Tris pH 8.0, 100 mM NaCl, 10% (v/v) glycerol, 0.5 mM 
DTT. 
To purify His6-UbcH5c protein, 2 L of pellet was thawed in 50 mL lysis buffer at 4℃, 
and then the resuspended cells were lysed by sonication on ice (10 seconds pulses at 
power 6.5 for 2 minutes). The crude lysate was centrifuged at 14,000 rpm for 30 minutes to 
precipitate insoluble fractions. The clarified lysate was added to approximately 2 mL of Ni-
NTA agarose resin (Qiagen) that had been washed once with 1 × TBS. The lysate and beads 
slurry was incubated at 4℃ for 1 hour with gentle mixing in order to allow binding of His6-
UbcH5c protein to the resin. The protein bound bead slurry was washed with 1L washing 
buffer with salt gradient from 500 mM to 100 mM. Retained protein was then eluted with 4 
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× 2 mL elution buffer. The eluted protein was combined and concentrated to 2 mL by a 
centrifugal concentrator with 3K MWCO (Pall Corporation). The concentrated protein was 
then loaded onto a Superdex 75 gel filtration column (GE Healthcare) for buffer exchange 
and further purification. The purity of pooled fractions 24 – 27 was confirmed > 95% by 
SDS-PAGE. The purified His6-UbcH5c was quantified by 280 nm absorbance, aliquot 100 µL 
in each PCR tube, and stored at -80℃ until use. 
 
Figure 2.21   His6-UbcH5c purification. a) Coomassie staining of different fractions. b) Gel filtration 
column trace and coomassie stain of each fraction. 
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3. β-catenin. β-catenin full length protein was expressed with an N-terminal MBP fusion 
protein separated by a TEV cleavage sequence in Escherichia coli strain BL21(DE3) pLysS 
(Stratagene) using construct pMAL-TEV-bCat. Transformed bacteria was grown at 37℃ 
until an OD600 = 0.6 was reached, at which point the culture was induced with 0.4 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG). Induced cells were grown at 18℃ for 16 
hours, and then cells were harvested by centrifugation at 3500 rpm/4℃ for 20 minutes. 
Cell pellets were washed with PBS once, then flash frozen in liquid nitrogen and stored at -
80℃ until use. 
 Lysis Buffer: 25 mM Tris pH 8.8, 300 mM NaCl, 2% (v/v) glycerol, 2 mM DTT, 1 mM 
PMSF and 1 pill protease inhibitor with a total volume of 50 mL for 2L culture. 
 Washing Buffer: 25 mM Tris pH 8.8, 2% (v/v) glycerol, 2 mM DTT.  
 Elute Buffer: 25 mM Tris pH 8.0, 100 mM NaCl, 10% (v/v) glycerol, 2 mM DTT, 10 
mM Maltose. 
 MonoQ Buffer A: 25 mM Tris pH 8.8, 2% (v/v) glycerol, 2 mM DTT. 
 MonoQ Buffer B: 25 mM Tris pH 8.8, 2% (v/v) glycerol, 2 mM DTT, 1M NaCl. 
 Gel Filtration Buffer: 25 mM Tris pH 8.8, 150 mM NaCl, 10% (v/v) glycerol, 2 mM 
DTT. 
To purify β-catenin protein, 2 L of bacteria pellet was thawed in 50 mL lysis buffer 
at 4℃, and then the resuspended cells were lysed by sonication on ice (10 seconds pulses 
at power 6.5 for 2 minutes). The lysate was centrifuged at 14,000 rpm for 30 minutes to 
precipitate insoluble fractions. The clarified lysate was loaded onto approximately 2 mL of 
amylose resin (New England Biochem) by gently rotating at 4℃ for 3 hours to ensure the 
binding of desired protein to the resin.  
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Figure 2.22   β-catenin purification. a) Coomassie staining of different fractions. b) MonoQ ion 
exchange column trace and coomassie stain of each fraction. c) Gel filtration column trace and 
coomassie stain of each fraction. 
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The protein bound bead slurry was washed with 1L washing buffer with salt 
gradient from 500 mM to 100 mM. Retained protein was then eluted with 4 mL elution 
buffer. The eluent was then incubated with 200 µL 1 mg/mL TEV protease at 4℃ for 12 
hours. The cleaved protein mixture was loaded directly onto a MonoQ 5/50 GL ion 
exchange FPLC column (GE Healthcare). The proteins were eluted with a linear gradient of 
0-60% MonoQ buffer B over 40 column volumes. The desired protein was pooled and 
concentrated to 1 mL using a centrifugal concentrator with 30K MWCO (Pall Corporation). 
The concentrated protein was then loaded onto a Superdex 200 gel filtration column (GE 
Healthcare) for buffer exchange and further purification. The purity of resulting pooled 
fractions 22 – 25 was confirmed > 95% by SDS-PAGE. The purified His6-UBA1 was 
quantified by 280 nm absorbance, aliquot 100 µL in each PCR tube, and stored at -80℃ 
until use. 
 
4. Biotin-β-catenin. Biotin-β-catenin was expressed similar as β-catenin protein described 
above. The differences were: 1) BL21(DE3) pLysS bacteria cells harboring two constructs, 
namely pMAL-TEV-bCat-AVI and pET28a-BirA, were grown in ampicillin and kanamycin 
double selection LB medium; 2) a final concentration of 50 µM Biotin (Sigma-Aldrich) was 
also added to the cells during IPTG induction. The purification was the same as β-catenin 
protein. 
 
5. GST-β-catenin. GST-β-catenin was expressed and purified similar as β-catenin protein 
described above. The differences were: 1) pGEX-5x-β-catenin construct was transformed 
into bacteria cells; 2) Glutathione Sepharose resin (GE Healthcare) was used to bind GST 
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fusion β-catenin protein instead of amylose resin; 3) 10 mM maltose in elution buffer was 
replaced by 10 mM reduced glutathione; 4) no TEV cleavage was performed. 
 
6. Myc-MDM2. N-terminal myc-tagged human MDM2 full length protein was expressed in 
Escherichia coli strain BL21(DE3) pLysS (Stratagene) using construct pMAL-TEV-myc-
MDM2. Transformed bacteria was grown at 37℃ until an OD600 = 0.6 was reached, at 
which point the culture was induced with a final concentration of 0.4 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). Induced cells were grown at 16℃ for 16 hours, before 
harvest by centrifugation at 3500 rpm/4℃ for 20 minutes. Cell pellets were washed with 
PBS once, then flash frozen in liquid nitrogen and stored at -80℃ until use.  
 Lysis Buffer: 25 mM Tris pH 8.0, 300 mM NaCl, 2% (v/v) glycerol, 2 mM DTT, 1 mM 
PMSF and 1 pill protease inhibitor with a total volume of 50 mL for 2L culture. 
 Washing Buffer: 25 mM Tris pH 8.0, 2% (v/v) glycerol, 2 mM DTT.  
 Elute Buffer: 25 mM Tris pH 8.0, 100 mM NaCl, 10% (v/v) glycerol, 2 mM DTT, 10 
mM Maltose. 
 MonoQ Buffer A: 25 mM Tris pH 8.0, 2% (v/v) glycerol, 2 mM DTT. 
 MonoQ Buffer B: 25 mM Tris pH 8.0, 2% (v/v) glycerol, 2 mM DTT, 1M NaCl. 
 Dialysis Buffer: 25 mM Tris pH 8.0, 150 mM NaCl, 10% (v/v) glycerol, 2 mM DTT. 
To purify myc-MDM2 protein, the pellet was thawed in lysis buffer at 4℃, and then 
the resuspended cells were lysed by sonication on ice (10 seconds pulses at power 6.5 for 2 
minutes). The lysate was centrifuged at 14,000 rpm for 30 minutes to precipitate insoluble 
inclusion bodies. The clarified lysate was added to approximately 2 mL of amylose resin 
(New England Biochem) that had been washed once with 1 × TBS. The lysate and beads 
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slurry was incubated at 4℃ for 3hour with gentle mixing in order to allow binding of 
desired protein to the resin.  
 
Figure 2.23   Myc-MDM2 purification. a) Coomassie staining of different fractions. b) MonoQ ion 
exchange column trace and coomassie stain of each fraction.  
The protein bound bead slurry was washed with 1L washing buffer with salt 
gradient from 300 mM to 100 mM. Retained protein was then eluted with 4 mL elution 
buffer. The eluent was then incubated with 200 µL 1 mg/mL TEV protease at 4℃ for 12 
hours. The eluent was loaded onto a MonoQ 5/50 GL ion exchange FPLC column (GE 
Healthcare). The proteins were eluted with a linear gradient of 0-60% MonoQ buffer B over 
40 column volumes. The desired protein was pooled and dialysed overnight at 4℃ for 
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buffer exchange. The dialysed MDM2 protein was then concentrated, quantified by 280 nm 
absorbance, aliquot 100 µL in each PCR tube, and stored at -80℃ until use. 
 
7. Myc-MDM2 C464A. This MDM2 mutant protein was expressed and purified using the 
same protocol as myc-MDM2 except that pMAL-TEV-myc-MDM2 C464A construct was 
transformed into bacteria cells. 
 
Fluorescence Polarization Assays. Peptide biding assays were performed in triplicates by 
incubating 10 nM fluorescein-labeled peptides with two-fold serial dilution of β-catenin full 
length protein or human MDM2 full length protein in FP binding buffer (25 mM Tris pH 8.0, 
300 mM NaCl, 2 mM DTT and 2% (v/v) Glycerol). Incubations were carried out in 384-well, 
black flat-bottom plates (Corning) with a total volume of 80 µL and equilibrated at 4℃ for 3 
hours. Polarization was measured on a Spectramax-M5 plate reader with λex = 485 nm and 
λem = 525 nm. Dissociation constants (Kd) were determined by nonlinear regression 
analysis of dose-response curves using Prism software (GraphPad). 
 
Competition Fluorescence Polarization Assays. Competitive fluorescence polarization 
assays were performed by incubation of varied concentrations of non-fluorescein labeled 
bisax peptides with a pre-equilibrated (30 minutes at 4℃) mixture of 90 nM β-catenin full 
length protein with 10 nM fluorescein labeled StAx-35 or 90 nM human MDM2 full length 
protein with 10 nM fluorescein labeled SAH-p53-8. Polarization measurements and 
calculations were performed as above for fluorescence polarization assays. 
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Establish Stable HEK293T cells constitutively expressing myc3-MDM2. HEK293T cells 
were grown in 6-cm plate in complete growth medium (DMEM, 10% FBS and 1% 
penicillin/streptomycin) and allowed to grow to ~80% confluency at the time of 
transfection. Transfection was performed using 3 µg of pCMV-myc3-MDM2 plasmid with 
JetPRIME transfection reagent (Polyplus Transfection). A fresh medium was changed 
approximately 5 hours after transfection. 24 hours post transfection, cell culture medium 
was exchanged to medium supplemented with 0.6 mg/mL of G418 (EMD Millipore). The 
medium was kept changing every other day for about 2 weeks. Once all cells were dead in 
the nontransfected control plate, the remaining cells in the transfected plate were 
trypsinized and diluted to 150 cells/mL. Meanwhile, five 96-well clear bottom plates 
(Corning) were filled with 80 µL of complete growth medium containing 0.6 mg/mL G418. 
Then 20 µL of diluted cells were added into each well and the plates were incubated in 37℃ 
incubator for about two weeks to allow colonies to form. Re-seeded the monoclonal cells in 
24-well clear bottom plates (Corning) and waited until reaching ~80% confluency, at 
which point, half of the cells were passaged to new 24-well plates, and the other half were 
lysed and accessed for myc3-MDM2 expression. The best expression monoclone (Figure 
2.24 Lane 5) was selected as stable HEK293T cells for use.   
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Figure 2.24  Myc3-MDM2 expression in different monoclonal cells as visualized by western blotting. 
 
Pull-down Assays. Glutathione functionalized agarose beads (Thermo) were washed once 
with pull-down buffer (25 mM Tris pH 8.0, 300 mM NaCl, 2 mM DTT, 2% (v/v) Glycerol and 
0.1% Tween-20), followed by incubation with 1 µM GST-β-catenin in 1 mL pull-down 
buffer  for 3 hours at 4℃. Excess protein was washed away from the beads three times with 
pull-down buffer. In the meantime, HEK293T cells which constitutively express myc-MDM2 
were lysed in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM PMSF, 1% Triton X-100) 
followed by removal of insoluble debris by centrifugation at 13, 000 × g. Then GST- β-
catenin immobilized beads were incubated with indicated concentration of bisax peptides, 
200 µL HEK293T cell lysates and pull-down buffer to make a total volume of 500 µL. 
Incubation was performed at 4℃ for 5 hours. The beads were washed repeatedly with pull-
down buffer before elution of bound proteins by heating in SDS gel loading buffer at 95℃ 
for 10 minutes. Bound MDM2 protein and β-catenin loadings were visualized by western 
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blotting following standard methods and using antibodies specific for myc-tag (2272S, Cell 
Signaling) and β-catenin (9581S Cell Signaling). 
 
Competition Pull-down Assays. Streptavidin coated M-280 Dynabeads (Invitrogen) was 
washed with pull-down buffer once before incubation with 1 µM biotin-β-catenin in 500 µL 
pull-down buffer for 30 minutes at 4℃. Excess protein was washed from the beads three 
times with pull-down buffer. The biotin-β-catenin immobilized beads were incubated with 
200 µL stable HEK293T cell lysates, 100 nM Bisax-8 and indicated concentration of StAx-35 
or SAH-p53-8. Pull-down buffer was added to a final volume of 500 µL. The mixture was 
gently rotated at 4℃ for 5 hours. The beads were washed repeated with pull-down buffer 
before elution of bound proteins by heating in SDS gel loading buffer at 95℃ for 10 minutes. 
Bound MDM2 protein and β-catenin loadings were visualized by western blotting following 
standard methods and using antibodies specific for myc-tag (2272S, Cell Signaling) and β-
catenin (9581S Cell Signaling). 
 
In Vitro Ubiquitination Assays for β-catenin. Streptavidin coated M-280 Dynabeads 
(Invitrogen) was washed with pull-down buffer once before incubation with 1 µM biotin-β-
catenin in 500 µL pull-down buffer for 1 hour at 4℃. Excess protein was washed from the 
beads three times with pull-down buffer. The biotin-β-catenin immobilized beads were 
incubated with 200 nM Uba1, 2 µM UbcH5c, 1 mg/mL ubiquitin (Boston Biochem), 1.4 µM 
MDM2, 1 µM indicated bisax peptide, 5 mM ATP, 250 mM NaCl, 50 µM ZnCl2 and 500 µM 
DTT in a total volume of 20 µL reaction buffer (50 mM Tris pH 8.0, 50 mM KCl, 5 mM MgCl2) 
at 37℃ for 2 hours. Then the beads were washed with pull-down buffer three times at 
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room temperature, followed by elution of bound proteins by heating in SDS gel loading 
buffer at 95℃ for 10 minutes. Ubiquitinated β-catenin bands were visualized by western 
blotting following standard methods and using antibodies specific for β-catenin (9581S Cell 
Signaling) and ubiquitin (3936S, Cell Signaling). 
 
In vitro Ubiquitination Assay for KRas and c-myc. In vitro ubiqutination assay for KRas 
and c-myc protein was performed following previous protocol50. Briefly, a mixture of 600 
nM substrate protein (KRas or c-myc), 200 nM Uba1, 2 µM UbcH5c, 1 mg/mL ubiquitin 
(Boston Biochem), increasing amount of MDM2 (1.4, 2.8 and 4.2 µM), 1 µM bisax-8 peptide, 
5 mM ATP, 250 mM NaCl, 50 µM ZnCl2 and 500 µM DTT in a total volume of 20 µL reaction 
buffer (50 mM Tris pH 8.0, 50 mM KCl, 5 mM MgCl2) was incubated at 37℃ for 2 hours. The 
resulting solution was added 10 µL 3 × SDS gel loading buffer and boiled at 95℃ for 10 
minutes. KRas or c-myc protein was visualized by western blotting following standard 
methods and using antibodies specific for KRas (3339S Cell Signaling) and c-myc (5605S, 
Cell Signaling). Meanwhile, control experiments without either bisax-8 or MDM2 were 
performed in parallel following the same protocol. The KRas and c-myc proteins were 
generously provided by John McGee in Verdine Lab. 
 
Cell Penetration Assays. HeLa cells grown in complete growth medium (DMEM, 10% FBS 
and 1% penicillin/streptomycin) were harvested, counted using a hemocytometer, and 
seeded in a black, clear bottom 384-well plate (Corning) with 2,000 cells per well. The plate 
was incubated overnight at cell incubator to allow attachment of the cells to the bottom of 
the well. The next morning, the cells were washed with PBS once, before incubated with 
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indicated concentrations of fluorescein-labeled peptides in fresh complete growth medium 
for 4 hours at 37℃. Cells were washed with PBS three times, fixed with 4% (w/v) 
paraformaldehyde and stained with Hoechst dye (Invitrogen). Then 100 µL PBS was added 
into each well and the plate was sealed with tape to avoid dryness. High content imaging 
measurements were performed to determine intracellular access on an IX5000 
epifluorescence microscope (Molecular Devices Corporation). Epifluorescent images were 
taken at 20 × magnification in triplicate, imported into MetaXpress software. A relative 
fluorescence intensity was calculated for positive cells which were identified based on cell 
size and signal/noise ratio.   
 General parameters for image acquisition:  
Wavelength One: DAPI, excitation for 20ms, laser-based and image-based autofocus, 
Wavelength Two: FITC, excitation for 5ms, offset from wavelength one = + 5 µm. 
 General parameters for image analysis in MetaXpress: 
Wavelength One: DAPI, minimum cell diameter = 6 µm, maximum cell diameter = 20 
µm, minimum intensity above local background = 1,000, 
Wavelength Two: FITC, minimum cell diameter = 6 µm, maximum cell diameter = 30 
µm, minimum intensity above local background = 500. 
 
β-catenin Degradation Assays. SW480 cells grown in complete growth medium (L-15, 10% 
FBS and 1% penicillin/streptomycin) were harvested, counted using a hemocytometer, and 
seeded in a clear bottom 96-well plate (Corning) with 10,000 cells per well. The plate was 
incubated overnight at cell incubator to allow attachment of the cells to the surface of the 
well. The next morning, the cells were washed with PBS once, before incubated with 
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indicated concentrations of bisax peptides in fresh complete growth medium for 7 hours at 
37℃. The cells were then washed with PBS three times followed by lysis in SDS gel loading 
buffer. The lysate were heated at 95℃ for 10 minutes, and β-catenin protein and β-actin 
loading control were visualized by western blotting following standard methods and using 
antibodies specific for β-catenin (9581S Cell Signaling) and β-actin (A5316, Sigma-Aldrich). 
 
Luciferase Reporter Gene Assay. Luciferase reporter gene assay using a plasmid 
containing tandem wild-type TCF-4 consensus binding sites at the promoter region of 
firefly luciferase gene were performed to evaluate intracellular β-catenin activity. SW480 
cells were plated in 6-cm plate and allowed to grow to ~80% confluency at the time of 
transfection. 3 µg of TOPflash plasmid and 2 µg pGLTK-renilla luciferase control plasmid 
were cotransfected into SW480 cells using JetPRIME transfection reagent (Polyplus 
Transfection) following manufacturer’s protocol. A fresh medium was changed 5 hours 
after transfection.  Cells were trypsinized approximately 24 hours after transfection and 
were re-seeded in 96-well clear bottom plate (Corning) with 10,000 cells per well. Cells 
were incubated at 37℃/5% CO2 for 24 hours to ensure that all the cells were fully settled 
down. Then medium was aspirated and bisax peptides and DMSO vehicle were added at 
indicated concentrations with a total volume of 40 µL. Compounds were incubated for 
another 24 hours before measurement of luciferase activities. Cells were washed gently 
with 100 µL PBS once and lysed using lysis buffer supplied in dual-luciferase assay kit 
(Promega). After lysis, firefly and renilla luciferase activities were measured according to 
manufacturer’s protocol. Firefly luciferase value was then normalized to renilla control 
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values in order to determine intracellular β-catenin activity in suppressing luciferase 
expression.  
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Chapter III    Studies on Cell Penetration by Stapled Peptides 
 
Stapled Peptides as a New Class of Cell Penetrating Peptides 
  Hydrocarbon-stapled α-helical peptides represent a new class of synthetic 
peptidomimetics capable of inhibiting protein-protein interactions1. Incorporation of α-
methyl, α-alkenyl amino acids at defined positions in a synthetic peptide permits side-chain 
crosslinking on-resin via ring-closing olefin metathesis2. Our group has shown that 
hydrocarbon “staples” spanning one or two helical turns increase α-helical content and 
protease resistance, enhance target binding affinity, and promote cell membrane 
penetration3-4. This technology has been successfully utilized to address many challenging 
problems in biological systems, including targeting multi-component transcription factor 
complexes and disrupting cryptic protein-protein interactions5-8. One important feature 
enabling stapled peptides to have such promising therapeutic potential involves their 
exceptional cell penetration properties. Indeed, several studies have demonstrated that 
stapled peptides show improved cell peremeability from their parent unmodified peptides.  
  The cell permeability of stapled peptides has been previously studied on 
fluorophore-labeled peptides using flow cytometry and confocal microscopy9. One 
advantage of flow cytometry is that for each condition, one can analyze a large number of 
cells, typically more than 1 × 104, which provides a statistically reliable evaluation of cell 
penetration over a large sample size. However, this method can only generate a 
distribution of fluorophore intensity without visible cell images showing subcellular 
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localization. Confocal microscopy, on the other hand, can provide a wealth of high-
resolution of cell images showing the localization of fluorophore-labeled peptides in great 
detail, which might provide clues as to the mechanism of cellular uptake and intracellular 
trafficking. However, one notable drawback for confocal microscopy is that it generally 
does not provide a quantitative analysis of cell penetration. In other words, one can only 
compare intracellular accumulations for different peptides by judging the fluorescence 
signal empirically. We therefore needed to develop a new image-based platform that can be 
used to evaluate the cell penetration property for stapled peptides quantitatively.  
  The improved cell permeability of stapled peptides enables them to exert potent 
and specific inhibition of protein-protein interactions in vivo, however, there is still much to 
learn regarding the mechanisms of cellular uptake itself. An energy-dependent endocytosis 
model for cell penetration by stapled peptides was establised based on preliminary results 
which showed impaired cell entry at 4℃ as well as the colocalization of fluorescein-labeled 
stapled peptides and the endosomal marker TRITC (tetramethylrhodamine 
isothiocyanate)-dextran9. Given the diversity in structure and chemical properties of 
stapled peptides, however, this mechanism required further validation in a larger samples. 
The gain of cell penetration is proposed to result from the unique features of stapled 
peptides. For example, the introduction of an all-hydrocarbon crosslink results in the 
constrained α-helix conformation, which embeds the hydrophilic amide backbone in the 
core of the folded structure. Furthermore, the hydrocarbon brace itself introduces a 
significantly hydrophobic patch to one face of the peptide. The exposure of the 
hydrophobic moiety as well as the mask of the hydrophilic peptide backbone may facilitate 
the interaction of stapled peptides with the hydrophobic interior of the cell membrane and 
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thereby enhance the cellular uptake.  
  Based on this hypothesis as well as the commonly-used strategy adding cationic 
residues into peptide squences to improve cell entry, extensive efforts have been made to 
optimize cell penetration for stapled peptides1, 4, 7. We tried all possible stapling positions 
and different stpaling types (stapled or stitched) in order to identify an optimized peptide 
conformation for cell penetration. In some cases, the glutamic acid and aspartic acid that 
were putatively uninvolved in binding to the target were replaced with glutamine and 
asparagine respectively to increase the net charge of the stapled peptides. In addition, an 
arginine residue, which is believed to facilitate cell entry via its terminal guanidinium 
group10, was also appended at end of stapled peptides in an attempt to increase their cell 
permeability. These strategies successfully increased the cell penetration for several 
stapled peptides, but not all sequences benefited from these strategies. Therefore, 
systematic studies of mechanisms of cell penetration by stapled peptides will need to be 
performed in order to design the next generation stapled peptides with enhanced cell 
permeability.  
 
Application of Stapled Peptides in Drug Delivery 
 Cell internalization of large hydrophilic therapeutic molecules such as nucleic acids 
and proteins is a challenging task because of the poor efficiency with which they 
translocate across cell membranes11-12. In order to address this problem, significant efforts 
have been made to develop carrier-mediated delivery systems which can assist entry of 
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macromolecules with potential therapeutic applications into cellular compartments. 
Among them, cell penetrating peptide-based delivery has aroused extensive interest12-14. In 
recent years, a large number of successful cases using cell penetrating peptides for drug 
delivery have been reported. For example, the TAT peptide, derived from cell penetrating 
HIV TAT protein, has been demonstrated to deliver large, active proteins into the cells of 
live mice15. The TAT peptide has also been used to carry phage-encapsulated DNA into cells, 
as well as liposome-encapsulated DNA for gene expression in mice16-17. In addition, several 
TAT fusion proteins and peptides have been used to treat mouse models of cancer, 
inflammation and other diseases18. Given the enormous therapeutic and diagnostic 
potential of cell penetrating peptides and the improved cellular uptake of stapled peptides, 
it is promising to develop a stapled peptide based drug delivery system to facilitate a 
variety of macromolecular cargoes across the cell membrane. 
 This chapter will describe our efforts to develop a high-throughput image-based 
assay to quantitatively measure the cell permeability of stapled peptides. By applying this 
assay to the stapled peptide library generated by our group, we are aiming to correlate 
intracellular accumulation with intrinsic physicochemical properties, and to explore 
potential mechanisms of cell penetration. In addition, the differences in cell penetration by 
stapled peptide and unmodified cell penetrating peptides will be discussed side-by-side. 
Lastly, a proof-of-principle experiment will be described in which stapled peptides are 
applied as cargo carriers to deliver a biologically active morpholino molecule into cells. 
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Development of an Image-Based High-Throughput Assay to Quantitatively Measure 
Cell Penetration of Stapled Peptides 
 Understanding the internalization process of cell penetrating peptides (CPPs), 
especially stapled peptides, has been a subject of great interest during the last decade. The 
majority of previous studies have been performed by either using high-resolution 
microscopy to show the existence of fluorophore-labeled CPPs inside cells, or by 
quantitatively measuring the fluorescence distributions by fluorescence-activated cell 
sorting (FACS). Although these methods provided qualitative cell penetration information, 
a new assay combining high-resolution imaging as well as quantitative measurement needs 
to be developed in order to better understand the cellular uptake properties for stapled 
peptides. In recent years, high-throughput cell-based imaging platforms have become 
increasingly popular to screen for small molecule modulators in various biological 
processes19-21. Taking advantage of one of these platforms, the Molecular Devices Image 
Express Micro high-throughput epifluorescent microscope, we sought to develop a high-
throughput quantitative assay to measure stapled peptide intracellular access.  
Human U2OS osterosarcoma cells were used in this assay because they have good 
adherence properties as well as suitable cellular morphology, making them suitable 
features for imaging experiments. Cells were seeded in black, clear-bottom 384-well plates 
overnight, and incubated with fluorescein-labeled peptides or DMSO vehicle for 12 hours. 
After the treatment, cells were washed thoroughly with PBS to remove excess peptides, 
fixed with 4% formaldehyde, and stained with Hoechst dye to visualize nuclei. Once 
prepared, the plates were imaged by epifluorescence microscopy according to developed 
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protocols. Briefly, the microscope camera takes cell images separately on both the Hoechst 
channel (blue) and the FITC channel (green), which can be merged later during the analysis. 
It first performs a Z-scan on the Hoechst channel to locate cells, and the parameters were 
adjusted to optimize the cell size and fluorescence intensity. Then the parameters from this 
acquisition were transferred to the FITC channel to locate and take images of FITC-labeled 
peptides in all samples. This assay can be done in a high-throughput manner, resulting in a 
panel of Hoechst/FITC images from individual wells (Figure 3.1).  
 
Figure 3.1   High-throughput epifluorescence microscopy images of stapled peptide intracellular 
access. a) Hoechst channel of a portion of a 384-well plate indicates the location and number of 
nuclei. b) The same portion of the 384-well plate shown in a) imaged in the FITC channel reveals 
different intracellular fluorescence accumulations. 
The cell images were then imported to an associated software program, MetaXpress, 
for fluorescence quantification and analysis. Cells were identified based on the Hoechst 
stain of nuclei. Nuclei that were of correct size and Hoechst intensity were considered 
“positive” cells. The cytoplasm was designated according to the location of FITC signals as 
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well as empiric parameters (Details in Material and Methods). The FITC intensities in the 
cytoplasm and nuclei were quantified separately and the sum of these two values yielded 
the FITC signal for the whole cell, which can be considered the relative intracellular peptide 
intensity. In addition, FITC negative cells were also identified for those can be visualized by 
Hoechst stain but were invisible in FITC channel (Figure 3.2).  
 
Figure 3.2   Quantitative measurement of cellular peptide intensity. a) Hoechst channel showing 
the location and size of nuclei. b) FITC channel showing the fluorescence intensity of the same cells. 
c) Information about cell size and fluorescence intensity were integrated to identify the FITC 
positive (Green mask) and negative (Red mask) cell. For positive cells, additional parameters 
allowed determination of the fluorescence intensity in nucleus (inner intense green) and cytoplasm 
(outer dimmer green).  
With this experimental and analysis setup, we found that the system generated 
highly reproducible and reliable results from assay-to-assay and with different stocks of 
the same stapled peptides. As shown in Figure 3.3a, there were negligible fluorescence 
differences among experiments for cells treated with DMSO vehicle, which could be used as 
a fluorescence background for all following experiments. In addition, the same stapled 
peptides from different batches of synthesis featured almost identical intracellular 
fluorescence signals in different tests (Figure 3.3b), which indicated that the assay 
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developed in this study produces repeatable and reliable results that can be directly 
combined and compared from a large set of experiments.  
Figure 3.3   The image-based high-throughput assay yielded reproducible and reliable results. a) 
the background fluorescence for DMSO vehicle were almost identical among different 
experiments. b) Four stapled peptides from different batches of synthesis generated similar 
intracellular fluorescence intensity in different tests.  
 
Analysis of Cell Penetration by Stapled Peptides 
 This quantitative high-throughput assay provides a reliable platform to perform a 
broad screen measuring cell penetration of stapled peptides and thereby investigating the 
mechanism beyond intracellular access. We collected and measured more than 200 distinct 
N-terminal FITC-labeled peptides belonging to three different classes, namely wild-type 
(unmodified), stapled and stitched peptides. We were aiming to compare the cell 
penetration capabilities for these peptides, and correlate the peptide intracellular access 
with their intrinsic chemical properties, which might inform future design of peptides with 
enhanced cell penetration.  
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The cell penetration assay was carried out using the same protocol as discussed 
above by treating cells with 1 µM FITC-labeled peptides for 12 hours in duplicate. Mean 
cellular fluorescence intensity was measured and the highly consistent DMSO background 
value was subtracted to yield a fluorescence signal for each peptide which was subject to 
comparison. Meanwhile, all peptides were converted to two-dimensional structures which 
were then imported to MarvinView software package (ChemAxon) for analysis of distinct 
theoretical physicochemical properties, such as molecular weight, formal charge at 
physiological pH, log P value, and 2D polar surface area (PSA), which are important 
parameters to evaluate “druglikeness” of small molecules according to Lipinski’s rule22. The 
results are listed in Appendix Table 1.  
In general, the unmodified, stapled and stitched peptide libraries present in this 
study had relatively similar physicochemical characteristics as shown in Figure 3.4. The 
mean molecular weight and calculated PSA values were nearly identical among the three 
peptide classes. A notable difference was observed among theoretical log P values, which 
were significantly higher for the stapled and stitched peptides relative to the unmodified 
peptides. This is not surprising as these modified peptides contain a solvent-exposed all 
hydrocarbon crosslink. Additionally, the stapled peptide class had a mean formal charge of 
approximately zero while the stitched and unmodified peptide classes exhibited a positive 
mean charge. Overall, the calculated physicochemical properties indicated that the peptide 
classes were quite similar in terms of their mean properties, which assures that the 
peptides chosen in this study were statistically significant and can be used to evaluate the 
penetration behavior for a broader collection of peptides. 
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Figure 3.4   Physicochemical parameters a) molecular weight, b) theoretical Log P, c) formal charge 
at pH 7.5, d) calculated PSA of wild-type, stapled and stitched peptides. The data are plotted in 
whiskers format. 
  With these physicochemical parameters in hand, we next analyzed the mean cellular 
fluorescence intensity obtained from epifluorescence imaging. Interestingly, stapled and 
stitched peptides exhibited a significant increase in cell penetration compared with wild-
type unmodified peptides (Figure 3.5a). Given that all three peptide classes have similar 
physicochemical properties in general, the benefit in cell penetration should be largely 
attributed to the synthetic stabilization of α-helical peptides, namely stapled peptide 
technology. Furthermore, we correlated the intracellular access with physical properties of 
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these peptides to figure out whether there exists any connection between cell penetration 
and intrinsic peptide properties. As a result, peptide charge appears to be the parameter 
correlated to intracellular access, which could be fitted into a Gaussian distribution with a 
population centroid at approximately +4 charged (Figure 3.5b). Specifically, peptides 
exhibiting a net negative charge (-7 to -1) showed little or no cellular uptake. Peptides of 
approximately neutral charge (-1 to +1) showed moderate cell penetration above 
background. Interestingly, peptides with a net positive charge (+1 to +7) showed 
significantly higher cell penetration as a group. Surprisingly, cellular uptake did not appear 
to increase linearly with charge, as the cell penetration decreases dramatically for peptides 
with charge greater than +7. This observation was not consistent with the previously 
reported models, which indicate that peptides with more positive charges have better 
penetration property due to the tighter electrostatic interaction with the negatively 
charged phospholipid membrane23-24. Although additional tests with a larger number of 
peptides could further confirm the results observed from this study, the unexpected 
relationship for highly charged peptides could result from the disruption of peptide 
packing during internalization or difficulty in dissociation from cell membrane. In addition, 
there was no discernible correlation between the penetration ability and peptide molecule 
weight, log P or PSA (Figure 3.5 c-e). The intracellular peptide levels were almost the same 
spanning a wide range in each class. Taken together, the stapling type and peptide charge 
are the key physical properties in determining peptide cell penetration ability, whereas the 
other parameters do not appear to have a significant effect. 
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Figure 3.5   Relationship between mean cellular fluorescence intensity and physicochemical 
properties of peptides. a) stapling pattern, b) formal charge at pH 7.5, c) molecular weight, d) 
theoretical log P, and e) 2D PSA.  
 In order to further investigate the cell penetration properties for stapled peptides 
and systematically analyze the similarities and differences in cellular uptake between 
stapled peptides and other wild-type cell penetrating peptides (CPPs), several stapled 
peptides and CPPs were picked out from our peptide library to study their penetration 
behaviors side-by-side in dose-dependent manner. TAT (48 – 60), Antennapedia (Antp) 
and Poly-Arg8 were used as wild-type (unstapled) peptides in this experiment since they 
are frequently used as model cell penetrating peptides in mechanism investigation and 
cargo delivery studies25-27. For stapled peptides, SAHM1, SAH-p53-8, SAHBa, TNG90 and 
TNG147 were chosen because they have different stapled patterns and exhibit distinct 
cellular uptake according the aforementioned broad screen. The experiments were carried 
out as described previously except that cells were incubated with a series of concentrations 
of peptides for 12 hours.  
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Figure 3.6   Dose-dependent cell penetration of a) wild-type and b) stapled peptides. 
The results are shown in Figure 3.6. Generally, both wild-type and stapled peptides 
did not appear to have any cellular uptake below 1 µM except for the SAHM1 peptide which 
showed modest penetration at 1 µM. Starting at 1 µM, they showed enhanced intracellular 
access with increased peptide concentrations. Although the increases were different for 
distinct peptides, stapled peptides featured much faster growth rate in general. It is 
interesting to point out that TNG147 were poorly permeable at 1 µM but showed dramatic 
increase at 5 µM, which might suggest that a concentration-dependent peptide packing or a 
receptor-mediated mechanism facilitating the cell penetrating process. Furthermore, it is 
worth noting that stapled peptides are more cell permeable than wild-type peptides at all 
concentrations, especially at higher doses.  
In addition, a time-course penetration assay was also performed to better 
understand peptide internalization kinetics. Antp and SAHM1 peptides were used as wild-
type and stapled examples in this assay since they showed better cellular uptake in each 
class in the concentration-dependent assay discussed above. Cells were treated with Antp 
or SAHM1 peptide at two concentrations (5 and 10 µM, respectively), harvested at different 
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incubation time points and were subjected to imaging and analysis. As shown in Figure 3.7, 
wild-type and stapled peptides showed completely different penetration properties for 
different incubation durations. 5 µM and 10 µM Antp peptides had nearly identical cellular 
uptake for 2 hours incubation. After 2 hours, the intracellular fluorescence for both 5 µM 
and 10 µM treatments started to decrease until reaching a stable stage around 8 hours, and 
the signal remained unchanged up to 24 hours. This pattern could be attributed to the 
balance between cell penetration and fast proteolysis of wild-type Antp peptide. For the 
first 2 hours, cellular uptake predominated the process, while simultaneously the peptide 
underwent degradation through proteolysis as they accumulated inside cells. Equilibrium 
was achieved at approximately 8 hours incubation where the rate of penetration was 
almost the same as proteolysis. Notably, fluorescence intensity for 5 µM treatment dropped 
faster and was lower at the stable stage compared with 10 µM incubation. This might result 
from the slower peptide uptake at a lower concentration after 2 hours due to the decreased 
concentration potential across cell membrane. However, SAHM1 peptide showed increased 
cellular uptake for the first 8 hours at both concentrations, although the intracellular 
fluorescein intensity accumulated faster for 10 µM incubation. Fluorescence signal values 
were much higher than those observed in Antp treatment. After 8 hours, the fluorescence 
signal remained unchanged for 5 µM treatment and was slightly decreased after 16 hours 
incubation. However, treatment of 10 µM SAHM1 still showed slightly increasing cellular 
uptake up to 24 hours. Although stapled SAHM1 peptides exhibited distinctly improved 
penetration properties over time, it can be explained by the same model for Antp peptides 
which refers that the observed cellular uptake process is actually the consequence of cell 
penetration and intracellular proteolysis. Stapled SAHM1 has an all hydrocarbon crosslink 
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in peptide sequence, resulting in better cellular uptake yet much slower proteolysis, which 
makes it continuously accumulated in cells at 10 µM. The slight decrease in fluorescence 
intensity after 16 hours for 5 µM incubation could be attributed to attenuated penetration 
resulted from the less concentration potential across cell membranes. 
 
Figure 3.7   Cell penetration for a) Antp and b) SAHM1 peptides over time at concentrations of 5 
and 10 µM. DMSO was also included in this assay as background reference.  
 Given the good cell penetration of SAHM1 peptide, a pulse-chase assay was 
performed to understand what the cellular uptake behaves if the peptide is removed from 
cell culture medium. The experiment was carried out using a similar protocol as before. 1 
µM SAHM1 peptide was used in this assay because it would not saturate the intracellular 
fluorescence at early stage of the incubation. 12 hours after initial incubation, the cell 
culture medium was aspirated and cells were extensively washed with PBS to completely 
remove excess SAHM1 peptide. Then fresh medium containing either a new batch of 1 µM 
peptide or DMSO vehicle were added to incubate with cells for additional time periods as 
indicated. Cells were imaged and mean cellular fluorescence intensity was quantified and 
plotted at different time spots. 
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Figure 3.8   A pulse-chase penetration assay for SAHM1 peptide in which fresh medium containing 
either a new batch of peptide or DMSO vehicle were exchanged at 12 hours after initial treatment. 
 As expected, the cellular uptake kept growing for the first 12 hours incubation. After 
medium exchange, cells incubated with fresh medium containing DMSO vehicle retained 
the intracellular fluorescence intensity. Interestingly the signal for cells treated with the 
new batch of SAHM1 peptide continued to increase (Figure 3.8). It can be explained by the 
same notion that the observed intracellular fluorescence is actually the equilibrium 
between cell penetration and proteolysis. Upon exchanging to peptide-free medium, there 
should be no new peptide penetration, but the fluorescence signal remained almost 
unchanged due to the slow proteolysis degradation for stapled peptides. However, when a 
new batch of peptide was added into cell culture medium, the cell penetration process 
became more robust, resulting in a continued increase in fluorescence intensity inside cells.  
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Mechanism study of Cell penetration of stapled peptides 
 According to the experiments shown above, we figured out that a) stapled peptides 
exhibit better cell penetration properties than wild-type peptides, b) the cell penetration 
depends largely on stapled pattern and peptide charge, c) the observed intracellular 
fluorescence is actually a result of equilibrium between cell penetration and cellular 
proteolysis which confers peptide cellular uptake in dose- and time-dependent manner. 
However, the mechanisms utilized by peptides to translocate across the cell membrane are 
still unclear. Herein, efforts were made to unveil the uptake mechanisms for cell 
penetrating peptides, especially for stapled peptides.  
 Wild-type CPPs, TAT, Antp and poly-Arginine for example, have been used as model 
peptides to study their uptake mechanism by several research groups. Some evidence 
indicated that they enter cells via an energy-dependent endocytosis, which is an active 
transport process. However, we cannot neglect the data supporting the passive diffusion 
mechanism. So far, no clear conclusion has been achieved based on previous research23, 28. 
Therefore, the first experiment in this study was designed to figure out whether the cell 
penetration process is an ATP-dependent endocytosis. Cells were pre-treated with NaN3 
together with 2-Deoxyglucose (2-DG) to reduce cellular ATP levels, and then incubated 
with FITC-labeled peptides for 4 hours. The intracellular fluorescence intensity was 
quantified and compared with that observed from normal cells without NaN3 and 2-DG 
treatment to clarify whether ATP depletion affected cell penetration. Similar as the 
aforementioned dose-dependent assay, TAT, Antp and poly-Arg8 peptides were used as 
wild-type CPPs in this experiment, and SAHM1, PEN2, SAHBa and SAH-p53-8 were chosen 
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as stapled peptide candidates due to their distinct cell penetration properties. As a result, 
cellular ATP levels were confirmed to be dramatically decreased by approximately 90% 
after NaN3 and 2-DG treatment as shown in Figure 3.9a. TAT and poly-Arg8 exhibited 
almost identical cellular uptake in ATP-depleted and normal cells, which supported the 
model that they utilized passive diffusion pathway to penetrate cells. However, Antp and all 
the stapled peptides showed less permeable in ATP-depleted cells with a decrease by a 
range of 20 – 50%, indicating an active trans-membrane process which required cellular 
ATP. Therefore, the evidence shown in this study reveals that stapled peptides penetrate 
cells via an ATP-dependent endocytosis, whereas the internalization of wild-type CPPs 
needs to be analyzed case-by case. 
 
Figure 3.9   Stapled peptides penetrate cells via an ATP-dependent endocytosis. a) Cellular ATP 
decreased by approximately 90% upon NaN3 and 2-Deoxyglucose (2-DG) treatment. b) Cellular 
uptake of CPPs in ATP-depleted and normal cells. 
 Energy-dependent endocytosis can be accomplished by several different pathways, 
for example, caveolin- and clathrin-mediated endocytosis. Further studies were performed 
to identify which specific pathway peptides utilize to penetrate cell membrane. A useful 
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tool to interrogate the endocytosis system is to take advantage of the small molecules that 
have been discovered to inhibit each possible pathway29-33 (Table 3.1).  
Table 3.1   Small molecule inhibitors in modulating energy-dependent endocytosis. 
 
Using these small molecules, I repeated the cell penetration experiments under a 
variety of conditions that each blocked a different endocytosis pathway. If the pathway by 
which CPPs enter cells was inhibited, a decrease in intracellular fluorescence would be 
observed. Otherwise, the intracellular access should keep the same. As a result, I found the 
internalization process for both wild-type and stapled peptides required sulfated 
proteoglycans on cell surface (Figure 3.10a). It is reasonable to connect this result with the 
previous conclusion that peptide charge is a key factor determining cell penetration. 
Proteoglycans are usually negatively charged under physiological conditions due to the 
occurrence of sulfate groups, which might form electrostatic pairs with positively charged 
peptides to facilitate them anchoring on the cell membrane. However, blocking the other 
possible pathways did not appear to have any effect on peptide cell penetration (Figure 
3.10 b-d).  
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Figure 3.10   Quantitative illustration showing cellular uptake for cell penetration peptides under 
various conditions that each blocked an endocytosis pathway. a) NaClO3 inhibits proteoglycan 
biosynthesis, b) Filipin and Nystatin prevent assembly of caveolin-coated invaginations, c) 
Chloropromazine prevents clathrin-coated pit formation, and d) Cytochalasin D blocks actin 
polymerization. 
In order to further confirm that sulfated proteoglycan is important to mediate 
cellular uptake for peptides, a secondary assay was performed by using wild-type CHO cells 
(CHO-K1) and proteoglycan-deficient CHO cells (pgsA-745) which have a defect in 
xylosyltransferase and thereby prevent glycosaminoglycan biosynthesis34. As a result, all 
peptides showed similar penetration properties in wild-type CHO cells as previous 
experiments in U2OS cells, but the uptake decreased by approximately 50% in 
proteoglycan-deficient CHO cells, which was consistent with the experiment by using small 
molecule inhibitor (Figure 3.11). Taken together, CPPs penetrate cells through a clathrin- 
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and caveolin-independent endocytosis pathway that requires anionic cell surface 
proteoglycans which might associate with peptides via electrostatic interactions and 
thereby facilitates the internalization. This result is very similar as cellular uptake for 
supercharged GFP (scGFP), which does not utilize clathrin- or caveolin-mediated 
endocytosis either. But scGFP internalization needs actin polymerization, which is not 
required for peptide penetration35.  
 
Figure 3.11  Cell penetration of wild-type and stapled peptides in wild-type CHO and proteoglycan-
deficient CHO cells. 
 
Peptide Stapling Improves Cell Penetration 
 Stapled peptides exhibit better cell penetration properties in general than wild-type 
peptides, we wonder whether peptide stapling strategy can be applied to any wild-type 
peptide to improve cellular uptake. To test this hypothesis, I designed a list of stapled 
peptides based on TAT, Antp and poly-Arg8 peptide sequence (Figure 3.12a). The stapled 
peptides and their parent unmodified peptides were incubated in U2OS cells for 12 hours 
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with a concentration range from 10 nM to 20 µM. The intracellular fluorescence intensity 
was then measured and plotted as dose-dependent curve for each peptide class.  
 
Figure 3.12   Improvement of cell penetration for wild-type peptide by stapling strategy is a case-
by-case scenario. a) Peptides investigated in this assay with sequence illustration. b) – d) dose-
dependent cell penetration assays for TAT, Antp and poly-Arg8 peptides and their stapled 
derivatives.  
As a result, all peptides showed a dose-dependent increase of cell penetration, 
which is as expected according to previous experiments (Figure 3.12 b-d). Interestingly, 
stapled peptides derived from Antp and poly-Arg8 peptide class showed improved cell 
permeability at concentration starting from 1 µM for Antp and 5 µM for poly-Arg8. Below 1 
µM, both wild-type peptides and stapled version did not appear to penetrate cells. It is 
noteworthy that the stapling position also affected the cellular uptake as the two stapled 
Antp peptides with different staple positions exhibited varied cell penetration, albeit both 
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of them were better than wild-type Antp. However, reduced cellular uptake was observed 
for stapled peptides derived from TAT sequence. This could be explained by many possible 
reasons, including that the residues replaced by S5 unnatural amino acids were actually 
essential in TAT internalization, and stapling at these positions disrupted peptide 
secondary structure or packing which was favored by the penetration process. Taken 
together, peptide stapling strategy indeed improves cellular uptake for some peptide 
sequences but it cannot be applied to every case since the cellular internalization is a 
complicated process regulated by many factors. 
 
Application of Stapled Peptides in Oligonucleotide Delivery 
 Cell penetrating peptides (CPPs) have become extremely popular in recent years 
due to their potential therapeutic application in drug delivery. Indeed, CPPs have been 
demonstrated to assisst to internalize many non-cell-permeable cargoes, including DNA, 
RNA and even proteins, resulting in profound biological activities inside cells. Although 
these CPPs show promising activities in several cases, there is still great room to advance 
this technology by improving the cell penetration. Given that stapled peptides exhibit much 
better cellular uptake than these widely used CPPs in general, a reasonable strategy is to 
apply stapled peptides as a new class of cargo carrier.  
 In this study, we aimed to set up a proof-of-principle experiment to demonstrate 
that stapled peptides can efficiently deliver a biologically meaningful oligonucleotide into 
cells, and show better cellular activity than oligonucleotide alone. Based on this pilot 
experiment, we will expand the cargo category to many other biologics with diverse 
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applications in the future. The oligonucleotide used in this study is a phosphorodiamidate 
morpholino oligomer (PMO) which induces dystrophin exon 23 skipping during processing 
of the primary transcript, and hence can treat a type of degenerative muscle diseases 
named as Duchenne Muscular Dystrophy (DMD)36. The genetic causes of this disease 
typically involve nonsense or frame-shift mutations within the Dystrophin gene, causing 
premature termination of translation and synthesis of a non-functional dystrophin protein. 
In particular, there is a spontaneous cytosine to thymidine mutation at position 3185 of 
Exon 23, which results in failure of full-length protein production37-39. One unique feature 
making the dystrophin protein unusual is that the internally deleted protein that maintains 
the reading frame is still functional40-41. Therefore, one solution to treat this disease is using 
antisense oligonucleotides to redirect gene transcript processing by blocking mutated 
exons in pre-mRNA splicing, which will result in a shortened version of dystrophin 
protein42-43. The morpholino chemistry produces a neutral oligonucleotide that has 
exceptional biological stability and has been applied to treat Duchenne Muscular Dystrophy 
in clinical trials44-45. However, the poor cellular delivery limits their further therapeutic 
applications. Therefore, we collaborated with Professor Keith Foster at University of 
Reading to conjugate one of our best cell penetrating stapled peptide (SAH-ARA) with the 
PMO molecule targeting exon 23 of dystrophin, and further investigate the biological 
activity of the conjugate in vivo.  
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Figure 3.13   Schematic illustration of the synthesis of SAH-ARA-PMO conjugate. a) Synthesis route 
for SAH-ARA-PMO conjugate. b) SAH-ARA peptide information. 
 The SAH-ARA peptide, derived from Androgen Receptor (AR) targeting peptides, 
was used in this study for several reasons46-47. First, it shows great cellular uptake in 
previous high-throughput cell penetration assay. Second, it is not functional in cells, with 
limited toxicity and no activity. Lastly, it is a peptide with only eight amino acids, which 
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would not interfere with any biological activity of the PMO. In addition, we used a non-
cleavable covalent linkage to conjugate SAH-ARA and the PMO together rather than 
formulation or cleavable linkage like disulfide bonds. This non-cleavable linkage is 
proposed to efficiently facilitate PMO molecule in the entire delivery process, including cell 
membrane internalization, release from endosomes, and translocation into nucleus. The 
SAH-ARA peptide was synthesized with an N-terminal cysteine for conjugation purpose, 
and a 20-atom-long PEG2 linker was added between the cysteine residue and core peptide 
sequence to avoid unnecessary interaction with the PMO molecule. Meanwhile, exon 23 
targeting PMO molecule was ordered from Gene Tools (Philomath, OR) with 5’- primary 
amine for conjugation and 3’- FITC for imaging purpose. PMO was first reacted with 
succinimidyl-4-(N-maleimidomethyl)Cyclohexane-1-carboxylate (SMCC) to generate a 
maleimide functional group at 5’- end, which allowed the reaction with the cysteine 
containing SAH-ARA peptide to form the final conjugate (Figure 3.13).  
Once the SAH-ARA-PMO conjugate was prepared, the cell penetration assay was 
performed to verify whether SAH-ARA can effectively deliver the PMO molecule into cells 
and to figure out the subcellular distribution of the conjugate. The experiment was carried 
out by treating U2OS cells with compound concentrations ranging from 500 nM to 10 µM 
for 12 hours. As a result, the PMO itself didn’t appear to penetrate cells even at a 
concentration as high as 10 µM. As expected, SAH-ARA showed robust cellular uptake 
starting from 500 nM. Promisingly, there was a fair amount of SAH-ARA-PMO conjugate 
accumulating inside cells at 5 and 10 µM although the uptake efficiency was about 10 times 
less than the SAH-ARA peptide. In addition, it is noteworthy that the conjugate was 
observed to spread over the entire cell, indicating that SAH-ARA not only facilitates PMO 
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molecule to translocate across the plasma membrane, but also contributes in endosomal 
release and nucleus transport as well (Figure 3.14).  
 
Figure 3.14   Cell penentration of SAH-ARA-PMO conjugate and its individual components. a) Image 
view of cellular fluorescein intensity for all compounds at various concentrations. b)Quantitative 
illustration showing relative cell penetration of each compound at different concentrations. 
 Given the effective cell penetration of SAH-ARA-PMO conjugate, in vivo assays were 
carried out at Professor Keith Foster’s lab to evaluate the biological activity of the 
130 
 
conjugate. One common assay to analyze the exon skipping activity is to use RT-PCR to 
visualize the production of the transcript. In particular, H2K cells from mdx mice harboring 
the non-sense mutation in exon 23 were incubated with 5 µM SAH-ARA-PMO conjugate or 
PMO alone at 37 ℃ for 4 hours, followed by culturing at differentiation medium for another 
48 hours. Then RT-PCR was performed to amplify and visualize the transcription product 
of dystrophin gene.  
 
Figure 3.15   Reverse-transcription-polymerase chain reaction (RT-PCR) analysis of H2K cells from 
an mdx mouse with treatment of SAH-ARA-PMO conjugate or PMO alone. The 901 bp product 
represents the full-length transcript, and the product of 688 bp indicates transcript that excludes 
exon 23.  
As shown in Figure 3.15, a band with 901 bp product was observed in all samples, 
indicating that the full-length transcript with exon 23 mutation was produced in both 
conjugate and PMO treated cells. However, a 688 bp product, representing the exon 23 
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skipping product, was only observed in cells treated with SAH-ARA-PMO conjugate. It is 
worth to mention that this exon skipping transcript was observed in all four replicates, 
meaning the results shown here was reproducible and reliable. According to this result, we 
concluded that the stapled peptide conjugated PMO can efficiently mask exon 23 during 
pre-mRNA splicing whereas the PMO molecule alone couldn’t, which can be attributed to 
the benefit of better cell penetration of the SAH-ARA-PMO conjugate. 
The exon skipping assay shown above indicates that the PMO conjugate is active in 
cells with a peptide leash. An in vivo assay was then performed to evaluate the biological 
activity of the PMO conjugate in mdx mouse model by intramuscular injection. The purpose 
of this assay was to figure out whether the PMO conjugate is functional in animal models, 
so both the conjugate and PMO control were forced into tissues by intramuscular injection, 
which means the cell penetration was not a hurdle here for exhibiting any in vivo activity. 
Female mdx mice were intramuscular injected a single dose of 20 µg either SAH-ARA-PMO 
conjugate or PMO molecule alone with a total volume of 50 µL at 16 weeks old. The mice 
were excised 4 weeks post-injection, and the muscle tissues were analyzed for dystrophin 
expression by immunohistochemistry staining with anti-dystrophin monoclonal antibody 
recognizing the C-terminus of the protein. Since the non-sense mutation in exon 23 causes 
an early termination of dystrophin protein translation and hence resulting in the failure to 
produce full length protein, the observed dystrophin protein in this assay should be the 
slightly truncated version translated from exon 23 skipped transcripts. As a result, the 
treatment by the unconjugated PMO yielded an efficient formation of dystrophin positive 
fibres, which was consistent with previous studies. Promisingly, SAH-ARA-PMO also 
successfully induced the expression of shortened dystrophin proteins, and the efficiency 
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was as good as the unconjugated PMO, indicating that SAH-ARA peptide facilitates PMO 
cellular trafficking but not interfering with its biological activity (Figure 3.16). 
 
Figure 3.16   Intramuscular injection of mdx mice with PMO and SAR-ARA-PMO conjugate. a) 
Expression of dystrophin in muscle fibres after treatment. b) Quantitative illustration showing the 
number of dystrophin positive fibres upon PMO and conjugate treatment. 
 Taken together, we demonstrated that a stapled peptide (SAH-ARA) with good cell 
permeability can efficiently deliver a poor penetrating PMO molecule into cells by covalent 
conjugation of the two components. Furthermore, the conjugate exhibited improved exon 
skipping activity in cell-based assay and induced expression of shortened dystrophin 
protein in mdx mice. An ongoing effort is made by intravenous injection of SAH-ARA-PMO 
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conjugate in order to demonstrate an improved in vivo efficacy as a result of better cellular 
uptake. 
 
Conclusion 
In this study, we investigated the cell penetration for stapled peptides, which is one 
of the most significant and poorly understood aspects of peptide stapling technology. In 
order to address this problem, we developed a high-throughput microscopy assay to 
quantitatively measure stapled peptide intracellular accumulation. We demonstrated that 
this assay yielded highly reproducible results when testing peptide intracellular access. 
Using this assay, we analyzed more than 200 discrete peptides with various sequences, 
stapling positions and patterns, and distinct physicochemical properties. As a result, we 
found that stapled peptides penetrate cells much better than wild-type ones, and the cell 
penetration ability is strongly related to stapling patterns and formal charge, whereas the 
other physical parameters do not appear to have a significant effect. We further studied the 
relation between cellular uptake and peptide concentration and incubation time, and 
figured that the intracellular accumulation is actually the consequence of equilibrium of 
peptide penetration and cellular proteolysis. In addition, a chemical genetic screen was 
performed to illustrate that stapled peptides penetrate cells through clathrin- and caveolin-
independent endocytosis pathway that requires sulfated proteoglycans on cell surface. 
Furthermore, we demonstrated that peptide stapling strategy improves cellular uptake for 
some wild-type peptide sequences by simply grafting the all hydrocarbon crosslink to the 
wild-type peptides. Finally, one stapled peptide, SAH-ARA derived from AR targeting 
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peptides, was demonstrated to deliver a non-penetrating morpholino molecule into 
mammalian cells without affecting its biological activity.  
 
Future Directions 
The work in this study shows a systematic study on cell penetration by stapled 
peptides, which enriches our understanding of stapled peptides as chemical probes and 
potential targeted therapeutics. In order to further explore the penetration properties for 
stapled peptides and apply the information learned in the design of next-generation stapled 
peptides with improved biological activities, future studies should be focused on the 
following aspects. 
1) Analysis of cell penetration for a larger set of peptides. In current study, we tested 
more than 200 distinct peptides with different stapling patterns and physicochemical 
properties, which indicated that stapled peptides are better cell penetrators than wild-type 
ones and the permeability is largely related to the formal charge at physiological pH. 
However, this peptide pool was not completely unbiased although the overall 
physicochemical properties for these peptides were quite similar in terms of the mean 
values. For example, some peptides were designed to gain extra cellular uptake by coupling 
additional arginine residues into peptide sequences. Furthermore, the distribution of 
peptides in each physical parameter range was not quite even. For example, the number of 
peptides with positive net charge was much larger than those negatively charged peptides. 
Therefore, a larger set of peptides with diverse intrinsic properties need to be analysed to 
generate more statistically meaningful results.  
135 
 
2) Identification of the mechanism of cell penetration by stapled peptides using 
unbiased methods. The mechanism of cell penetration by stapled peptides is one of the 
most important aspects in peptide stapling technology, however it is still not very clear so 
far. We were making efforts to address this question by biasedly using small molecule 
inhibitors to block each possible trafficking pathway and as a result, we got several pieces 
of information regarding this complicated penetration process. In order to elucidate the 
uptake process systematically, following studies should be performed by employing an 
unbiased screen method, like genome-wide RNAi screen, to identify all proteins affecting 
the intracellular accumulation of stapled peptides. The results of this unbiased screen will 
generate a global map of the genes facilitating the uptake and intracellular retention of 
stapled peptides, and thereby dramatically advance our ability to design next-generation 
compounds with enhanced potency.   
3) Application of stapled peptides in the delivery of diverse non-penetrating 
biologics. In this study, we showed an 8-mer stapled peptide derived from AR targeting 
peptides can efficiently facilitate the cellular trafficking of a non-penetrating PMO molecule 
without interfering with its intracellular exon skipping activity. This study opened a 
promising avenue to further the application of stapled peptides in the delivery of a larger 
collection of biologics, for example, siRNAs for targeted gene knockdown, and proteins with 
diverse biological activities. Furthermore, given the exceptional penetration of stapled 
peptides, it is entirely possible and promising to utilize stapled peptides in in vivo delivery, 
such as targeted tissue delivery, and translocation through brain-blood-barrier. In addition, 
with ongoing efforts to unveil the mechanism of cell penetration by stapled peptides, we 
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can also design novel stapled peptides suitable for different delivery applications in the 
future.  
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Materials and Methods: 
Peptides. Wild-type CPPs and stapled peptides were synthesized manually by standard 
solid phase peptide synthesis using Fmoc-chemistry. They were HPLC purified and 
verified >95% purity as indicated by LC/MS. The peptide sequences are listed in Table 3.2.  
Table 3.2   Peptides used in this study and their sequences.  
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PMO MDEX23. The PMO molecule targeting exon 23 of dystrophin gene was ordered from 
Gene Tools (Philomath, OR).  The sequence is GGCCAAACCTCGGCTTACCTGAAAT with 5’-
primary amine and 3’-fluorescein modification for conjugation and imaging purposes. The 
chemical structure of this PMO molecule is shown in Figure 3.17.  
 
Figure 3.17   Chemical structure of PMO molecule used in this study. 
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Cell Penetration Assays. The cell penetration assay was performed following the same 
protocol as that in Chapter two except U2OS cells were used. For dose-dependent assay, 
peptides were treated at 10 nM, 100 nM, 1 µM, 5 µM, 10 µM and 20 µM for 12 hours before 
analysis. For time-course assay, peptide was added at final concentration of 5 µM or 10 µM, 
and cells were harvested for analysis 2, 4, 8, 16, 20 and 24 hours post-treatment. The pulse-
chase experiment was performed similar as normal penetration assay. 12 hours after initial 
treatment, cell culture medium was aspirated and cells were washed extensively to remove 
excess FITC-labeled peptides. A fresh medium containing either a new batch of peptide or 
DMSO vehicle was added to incubate for longer time as indicated. Cells were imaged and 
analyzed 8, 12, 16, 20 and 24 hours after the initial treatment. For cell penetration assay 
with small molecule inhibitors, cells seeded in 384-well clear bottom plates (Corning) were 
pre-incubated with indicated small molecules for 1 hour (10 mM NaN3 and 30 mM 2-DG for 
ATP depletion, 5 µg/mL filipin or 25 µg/mL nystatin for blocking caveolin-mediated 
endocytosis, 5 µg/mL chlorpromazine for blocking clathrin-dependent endocytosis, 10 
µg/mL cytochalasin D for inhibiting actin polymerization, and 80 mM NaClO3 for disrupting 
proteoglycan synthesis). Then a final concentration of 10 µM FITC-labeled peptide was 
added to the cell culture medium containing the small molecule inhibitor and incubated for 
additional 4 hours. Cells were then washed, stained and analyzed by the same protocol as 
before. All cell penetration assays were performed in duplicate or triplicate, and the data 
were plotted in GraphPad Prism 5 (GraphPad software). 
ATP Depletion Assay. U2OS cells were seeded in a 96-well white opaque plate (Corning) 
with 10,000 cells per well. The plate was incubated overnight at cell incubator to allow 
attachment of the cells to the bottom of the well. The next morning, the cells were washed 
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with PBS once, followed by incubation with a fresh medium containing 10 mM NaN3 and 30 
mM 2-Deoxyglucose (2-DG) for 1 hour. The cellular ATP level was then measured using 
CellTiter-Glo Luminescent Kit (Promega) following the manufacturer’s protocol. 
 
Figure 3.18   HPLC trace showing the purity of components in SAH-ARA-PMO conjugation, a) PMO, 
b) PMO-SMCC, c) SAH-ARA, and d) SAH-ARA-PMO.  
Conjugation of SAH-ARA-PMO. A 8 mL 50%  acetonitrile/PBS (v/v) solution 
containing 0.5 mL 1 mM PMO with 5’-primary amine and 2 mL 5 mg/mL succinimidyl-4-(N-
maleimidomethyl) Cyclohexane-1-carboxylate (SMCC) was allowed to gently mix at room 
temperature for 1 hour to generate PMO-SMCC. The PMO-SMCC product was then purified 
with a 2% - 70% linear acetonitrile gradient in 0.1 M triethylammonium acetate (TEAA) 
buffer pH 7.0 over 20 minutes by reverse phase HPLC using a C-18 column (Agilent, Palo 
Alto, CA). The pooled fractions were concentrated and lyophilized to dryness. The 
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lyophilized powder was resuspended in H2O to a final concentration approximately 500 µM. 
Then a 1:1 mixture of PMO-SMCC and N-terminal Cysteine SAH-ARA in 50% 
acetonitrile/PBS (v/v) was incubated at room temperature overnight to yield final product 
SAH-ARA-PMO conjugate. The conjugate was purified by HPLC again following the same 
protocol. The purity of conjugate product was confirmed using LC/MS results (Figure 3.18). 
The purified conjugate product were lyophilized, re-dissolved in DMSO, quantified by 254 
nm and 494 nm absorbance and stored at -20℃ until use. 
Exon Skipping Assay. H2K cells from mdx mice harboring the non-sense mutation in exon 
23 were harvested and seeded in 48-well clear bottom plate (Corning). The cells were 
incubated at 37℃/5% CO2 overnight to allow attachment of cells to the bottom of the well. 
The next morning, cells were treated with a fresh medium containing 5 µM SAH-ARA-PMO 
or 5 µM PMO alone. Cell culture medium containing DMSO vehicle was also included as 
control. After 4 hours incubation, cells were transferred to differentiation medium for 48 
hours. Then total RNA was extracted from the cells and approximately 200 ng RNA 
subjected to RT-PCR using dystrophin exon-specific primers following manufacturer’s 
protocol. An aliquot of the resulting cDNA was used as a template for a second round of 
PCR amplification. Full length dystrophin gene transcript and the exon 23 skipping gene 
product were analyzed on 1% agarose gels in Tris-borate/EDTA buffer. The experiments 
were performed with four replicates for both SAH-ARA-PMO conjugate and PMO molecule 
alone.  
Intramuscular Injection Assay. Female mdx mice (16 weeks) were injected with 20 µg of 
SAH-ARA-PMO (or PMO) suspended in PBS with a total volume of 50 µL (n = 4). Four weeks 
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after injection, muscles were harvested and processed for cryosectioning. Expressed 
dystrophin protein was visualized by immunohistochemistry staining with a mouse 
antidystrophin monoclonal 10-11c antibody at 1:100 dilutions. The dystrophin positive 
fibers were counted as reported.  
 
 
 
  
143 
 
Reference 
1. Verdine, G. L.; Hilinski, G. J., Stapled Peptides for Intracellular Drug Targets. Method 
Enzymol 2012, 503, 3-33. 
2. Schafmeister, C. E.; Po, J.; Verdine, G. L., An all-hydrocarbon cross-linking system for 
enhancing the helicity and metabolic stability of peptides. J Am Chem Soc 2000, 122 
(24), 5891-5892. 
3. Kim, Y. W.; Verdine, G. L., Stereochemical effects of all-hydrocarbon tethers in i,i+4 
stapled peptides. Bioorg Med Chem Lett 2009, 19 (9), 2533-2536. 
4. Bernal, F.; Tyler, A. F.; Korsmeyer, S. J.; Walensky, L. D.; Verdine, G. L., Reactivation of 
the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 2007, 
129 (9), 2456-+. 
5. Walensky, L. D.; Pitter, K.; Morash, J.; Oh, K. J.; Barbuto, S.; Fisher, J.; Smith, E.; 
Verdine, G. L.; Korsmeyer, S. J., A stapled BID BH3 helix directly binds and activates 
BAX. Mol Cell 2006, 24 (2), 199-210. 
6. Moellering, R. E.; Cornejo, M.; Davis, T. N.; Del Bianco, C.; Aster, J. C., et al., Direct 
inhibition of the NOTCH transcription factor complex. Nature 2009, 462 (7270), 
182-U57. 
7. Grossmann, T. N.; Yeh, J. T. H.; Bowman, B. R.; Chu, Q.; Moellering, R. E.; Verdine, G. L., 
Inhibition of oncogenic Wnt signaling through direct targeting of beta-catenin. P 
Natl Acad Sci USA 2012, 109 (44), 17942-17947. 
8. Chang, Y. S.; Graves, B.; Guerlavais, V.; Tovar, C.; Packman, K., et al., Stapled alpha-
helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for 
p53-dependent cancer therapy. P Natl Acad Sci USA 2013, 110 (36), E3445-E3454. 
9. Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; Wagner, 
G.; Verdine, G. L.; Korsmeyer, S. J., Activation of apoptosis in vivo by a hydrocarbon-
stapled BH3 helix. Science 2004, 305 (5689), 1466-1470. 
10. Stanzl, E. G.; Trantow, B. M.; Vargas, J. R.; Wender, P. A., Fifteen Years of Cell-
Penetrating, Guanidinium-Rich Molecular Transporters: Basic Science, Research 
Tools, and Clinical Applications. Accounts of chemical research 2013. 
11. Hassane, F. S.; Saleh, A. F.; Abes, R.; Gait, M. J.; Lebleu, B., Cell penetrating peptides: 
overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci 2010, 
67 (5), 715-726. 
12. Deshayes, S.; Morris, M. C.; Divita, G.; Heitz, F., Cell-penetrating peptides: tools for 
intracellular delivery of therapeutics. Cell Mol Life Sci 2005, 62 (16), 1839-1849. 
144 
 
13. Gupta, B.; Levchenko, T. S.; Torchilin, V. P., Intracellular delivery of large molecules 
and small particles by cell-penetrating proteins and peptides. Advanced drug 
delivery reviews 2005, 57 (4), 637-651. 
14. Snyder, E. L.; Dowdy, S. F., Cell penetrating peptides in drug delivery. Pharm Res 
2004, 21 (3), 389-393. 
15. Snyder, E. L.; Dowdy, S. F., Recent advances in the use of protein transduction 
domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert 
opinion on drug delivery 2005, 2 (1), 43-51. 
16. Eguchi, A.; Akuta, T.; Okuyama, H.; Senda, T.; Yokoi, H., et al., Protein transduction 
domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian 
cells. J Biol Chem 2001, 276 (28), 26204-26210. 
17. Glover, D. J.; Lipps, H. J.; Jans, D. A., Towards safe, non-viral therapeutic gene 
expression in humans. Nat Rev Genet 2005, 6 (4), 299-U29. 
18. Wadia, J. S.; Dowdy, S. F., Transmembrane delivery of protein and peptide drugs by 
TAT-mediated transduction in the treatment of cancer. Advanced drug delivery 
reviews 2005, 57 (4), 579-96. 
19. Zhang, L. H.; Yu, J.; Pan, H. L.; Hu, P.; Hao, Y., et al., Small molecule regulators of 
autophagy identified by an image-based high-throughput screen. P Natl Acad Sci USA 
2007, 104 (48), 19023-19028. 
20. Carpenter, A. E., Image-based chemical screening. Nat Chem Biol 2007, 3 (8), 461-
465. 
21. Xia, X. F.; Wong, S. T., Concise Review: A High-Content Screening Approach to Stem 
Cell Research and Drug Discovery. Stem Cells 2012, 30 (9), 1800-1807. 
22. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Experimental and 
computational approaches to estimate solubility and permeability in drug discovery 
and development settings. Advanced drug delivery reviews 2001, 46 (1-3), 3-26. 
23. Madani, F.; Lindberg, S.; Langel, U.; Futaki, S.; Graslund, A., Mechanisms of cellular 
uptake of cell-penetrating peptides. J Biophys 2011, 2011, 414729. 
24. Vives, E., Cellular uptake of the Tat peptide: an endocytosis mechanism following 
ionic interactions. J Mol Recognit 2003, 16 (5), 265-271. 
25. Futaki, S., Membrane-permeable arginine-rich peptides and the translocation 
mechanisms. Advanced drug delivery reviews 2005, 57 (4), 547-558. 
26. Vives, E.; Schmidt, J.; Pelegrin, A., Cell-penetrating and cell-targeting peptides in 
drug delivery. Bba-Rev Cancer 2008, 1786 (2), 126-138. 
145 
 
27. Lindgren, M.; Hallbrink, M.; Prochiantz, A.; Langel, U., Cell-penetrating peptides. 
Trends Pharmacol Sci 2000, 21 (3), 99-103. 
28. Heitz, F.; Morris, M. C.; Divita, G., Twenty years of cell-penetrating peptides: from 
molecular mechanisms to therapeutics. Brit J Pharmacol 2009, 157 (2), 195-206. 
29. Kondo, T.; Beutler, E., Depletion of Red-Cell Atp by Incubation with 2-Deoxyglucose. 
J Lab Clin Med 1979, 94 (4), 617-623. 
30. Kang, J.; Heart, E.; Sung, C. K., Effects of cellular ATP depletion on glucose transport 
and insulin signaling in 3T3-L1 adipocytes. Am J Physiol-Endoc M 2001, 280 (3), 
E428-E435. 
31. Schnitzer, J. E.; Oh, P.; Pinney, E.; Allard, J., Filipin-Sensitive Caveolae-Mediated 
Transport in Endothelium - Reduced Transcytosis, Scavenger Endocytosis, and 
Capillary-Permeability of Select Macromolecules. J Cell Biol 1994, 127 (5), 1217-
1232. 
32. Vercauteren, D.; Vandenbroucke, R. E.; Jones, A. T.; Rejman, J.; Demeester, J.; De 
Smedt, S. C.; Sanders, N. N.; Braeckmans, K., The Use of Inhibitors to Study Endocytic 
Pathways of Gene Carriers: Optimization and Pitfalls. Mol Ther 2010, 18 (3), 561-
569. 
33. Lamaze, C.; Fujimoto, L. M.; Yin, H. L.; Schmid, S. L., The actin cytoskeleton is 
required for receptor-mediated endocytosis in mammalian cells. J Biol Chem 1997, 
272 (33), 20332-20335. 
34. Cuellar, K.; Chuong, H.; Hubbell, S. M.; Hinsdale, M. E., Biosynthesis of chondroitin 
and heparan sulfate in chinese hamster ovary cells depends on xylosyltransferase II. 
J Biol Chem 2007, 282 (8), 5195-200. 
35. McNaughton, B. R.; Cronican, J. J.; Thompson, D. B.; Liu, D. R., Mammalian cell 
penetration, siRNA transfection, and DNA transfection by supercharged proteins. P 
Natl Acad Sci USA 2009, 106 (15), 6111-6116. 
36. Gebski, B. L.; Mann, C. J.; Fletcher, S.; Wilton, S. D., Morpholino antisense 
oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum 
Mol Genet 2003, 12 (15), 1801-1811. 
37. Hoffman, E. P.; Brown, R. H.; Kunkel, L. M., Dystrophin - the Protein Product of the 
Duchenne Muscular-Dystrophy Locus. Cell 1987, 51 (6), 919-928. 
38. Sicinski, P.; Geng, Y.; Rydercook, A. S.; Barnard, E. A.; Darlison, M. G.; Barnard, P. J., 
The Molecular-Basis of Muscular-Dystrophy in the Mdx Mouse - a Point Mutation. 
Science 1989, 244 (4912), 1578-1580. 
146 
 
39. Heemskerk, H. A.; de Winter, C. L.; de Kimpe, S. J.; van Kuik-Romeijn, P.; Heuvelmans, 
N.; Platenburg, G. J.; van Ommen, G. J.; van Deutekom, J. C.; Aartsma-Rus, A., In vivo 
comparison of 2'-O-methyl phosphorothioate and morpholino antisense 
oligonucleotides for Duchenne muscular dystrophy exon skipping. The journal of 
gene medicine 2009, 11 (3), 257-66. 
40. Nowak, K. J.; Davies, K. E., Duchenne muscular dystrophy and dystrophin: 
pathogenesis and opportunities for treatment - Third in Molecular Medicine Review 
Series. Embo Rep 2004, 5 (9), 872-876. 
41. Heemskerk, H.; de Winter, C. L.; van Ommen, G. J. B.; van Deutekom, J. C. T.; Aartsma-
Rus, A., Development of Antisense-Mediated Exon Skipping as a Treatment for 
Duchenne Muscular Dystrophy. Ann Ny Acad Sci 2009, 1175, 71-79. 
42. Lu, Q. L.; Mann, C. J.; Lou, F.; Bou-Gharios, G.; Morris, G. E.; Xue, S. A.; Fletcher, S.; 
Partridge, T. A.; Wilton, S. D., Functional amounts of dystrophin produced by 
skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003, 9 (8), 
1009-1014. 
43. Mann, C. J.; Honeyman, K.; Cheng, A. J.; Ly, T.; Lloyd, F.; Fletcher, S.; Morgan, J. E.; 
Partridge, T. A.; Wilton, S. D., Antisense-induced exon skipping and synthesis of 
dystrophin in the mdx mouse. P Natl Acad Sci USA 2001, 98 (1), 42-47. 
44. Summerton, J.; Weller, D., Morpholino antisense oligomers: design, preparation, and 
properties. Antisense & nucleic acid drug development 1997, 7 (3), 187-95. 
45. Cirak, S.; Arechavala-Gomeza, V.; Guglieri, M.; Feng, L.; Torelli, S., et al., Exon 
skipping and dystrophin restoration in patients with Duchenne muscular dystrophy 
after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, 
phase 2, dose-escalation study. Lancet 2011, 378 (9791), 595-605. 
46. He, B.; Minges, J. T.; Lee, L. W.; Wilson, E. M., The FXXLF motif mediates androgen 
receptor-specific interactions with coregulators. J Biol Chem 2002, 277 (12), 10226-
35. 
47. Estebanez-Perpina, E.; Moore, J. M.; Mar, E.; Delgado-Rodrigues, E.; Nguyen, P., et al., 
The molecular mechanisms of coactivator utilization in ligand-dependent 
transactivation by the androgen receptor. J Biol Chem 2005, 280 (9), 8060-8. 
 
 
147 
 
 
148 
 
 
149 
 
 
150 
 
 
151 
 
 
152 
 
 
153 
 
 
